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Introduction and outline 
of this thesis
The early history of influenza epidemics
Epidemics of febrile acute respiratory tract infection (ARTI) have been known through -
out recorded history as ‘febris catarrhalis epidemica’, referring to descriptions by
Hippocrates in 412 BC [1]. Since the late 15th century, these epidemics were characterized
as mild self-limiting illnesses of the upper respiratory tract which could progress to
severe bronchitis or pleuritis with old age predisposing towards mortality [2]. In the 18th
century, the French word ‘la grippe’ and Italian word ‘influenza’ became widely adopted
in Europe. The etymology of ‘influenza’ lies with the description ‘influenza di catarro’,
referring to medieval beliefs that unfavourable astrological or miasmic influences
resulted in these disease outbreaks [3].
Accurate descriptions of influenza epidemics appeared in the 18th century. The rapid
spread among all layers of society prompted Grant (1782) and Johnson (1789) to postulate
airborne or contact transmission [1, 4]. Medics remained divided on the role of conta-
gionism, until the germ theory was proven by Snow (1855), Pasteur (1876) and Koch
(1890). A large influenza epidemic in 1889 received global media attention and was the
first recognized pandemic in a modern connected world (Figure 1) [5]. Expeditious
studies by Pfeiffer at the laboratory of Koch theorized that a bacterium Haemophilus
influenzae was the etiologic agent. Ironically, the assumption did not fulfil Koch’s postu-
lates and a ‘contagium vivum fluidum’ was not considered since the 1889 pandemic
predated the discovery of viruses in plants (Ivanovsky, 1892; Beijerinck, 1898), animals
(Loeffler, 1898) and humans (Reed, 1901). 
Figure 1.   The 1889 influenza pandemic media reports predated modern photojournalism.   
Source: adated from Le Petit Parisien, Dimanche 12 Janvier 1890. Described in [5].
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Virus discovery
The bacterium H. influenzae was discredited as the cause of human influenza infections
by clinical and comparative pathology studies in the wake of the 1918 influenza
pandemic [6]. Accumulating data indicated that an unknown agent caused influenza
infection and a wide range of pneumonic bacterial co-infections [6–  8]. High mortality
rates during the 1918 pandemic renewed the expeditious pursuit of a causative
agent [9, 10]. The search for a viral agent was fuelled by leading medical journals stating
‘in the course of evolutionary processes there suddenly is liberated a form of infectious
agent against which large numbers of people offer little or no resistance and which is
transmitted readily from person to person’ [11].
Berkefeld virus filters (Figure 2) were important to affirm that a ‘contagium vivum
fluidum’ transferred influenza infection among birds, mammals and humans. Filter
passing agents transferred fowl plague among chickens (1901, Centanni and Lode), 1918
pandemic influenza among humans (1918, Selter and Nicolle), and swine or human
influenza among pigs and ferrets (1931, Shope; 1933, Smith) [12– 16]. The work by Smith
(1935) and Dochez (1936) provided clear evidence of a viral etiology by showing that virus
filtrates of human influenza infection specimens could serially be cultivated in
 embryonated eggs or chick embryo tissue and cause influenza infection in ferrets and
human volunteers [17– 18]. The discovery of virus culture and hemagglutinin inhibition
intensified scientific studies on influenza virus characteristics, clinical manifestations,
epidemiology, vaccine development and host immunity [18, 19].
Figure 2. Berkefeld ‘bacterial water’ or ‘virus’ filter.
Source: adated from [20].
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Virus characteristics
The virus family Orthomyxoviridae consists of enveloped viruses with a single-stranded
negative sense segmented RNA genome and include Influenzavirus A, Influenzavirus B,
Influenzavirus C, Isavirus, Thogotovirus and Quaranjavirus. Human influenza infection is
mainly caused by influenza A and B viruses. Influenza A viruses have the unique
capability to exchange gene segments with avian and mammalian strains which allow
new subtypes to emerge against which humans have no pre-existing immunity.
The pandemic potential of a new influenza A virus is determined by its tropism for  2,6-
linked sialic acid (SA receptor) expressed in the human respiratory tract required for
efficient human-to-human transmission.
Influenza A virus has a 13kb genome with 8 segments which encode 14 proteins
(Figure 3) [21–23]. Virus subtypes are based on 18 hemagglutinin (HA) and 11 neura -
minidase (NA) surface glycoproteins which mediate sialic acid receptor binding or
cleavage. Matrix protein (M1) provides envelope rigidity and aids assembly. Matrix
transmembrane proteins (M2, M42) allow proton influx to uncoat virus particles during
entry. Nucleoprotein (NP) forms structure complexes with viral RNA and polymerase
enzymes (PB1, PB2, PA) modulate transcription and “cap snatching” of host cell mRNA.
The nuclear export protein (NEP/NS2) mediates host cell transport of ribonucleoprotein
complexes. PB1-F2 proteins mediate host cell apoptosis and nonstructural protein 1 (NS1)
disrupts type I interferon antiviral signaling and antigen presentation. PB1-N40 and PA-
X act as negative virulence regulators. 
Figure 3. Influenza virus structure and genome segments.     
Source: adated from [24].
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Laboratory diagnostics
Conventional influenza virus laboratory diagnostics include cell culture, antigen
detection or serum hemagglutination inhibition tests (HI). Trypsin-based cell culture
has low sensitivity and speed but is useful for virus subtyping and phenotypic antiviral
susceptibility testing. Antigen detection by immunofluorescence or enzyme immuno -
assay (EIA) is fast but the sensitivity may be limited. Serum antibody detection by
complement fixation test, enzyme-linked immunosorbent assay (ELISA) or HI (Figure 4)
is useful to confirm recent influenza infection but not for rapid diagnosis. 
Polymerase chain reaction (PCR) tests provide sensitive and specific detection of a wide
range of respiratory viruses. Real-time PCR developed at Leiden University Medical
Center provide a 100 to 1000 fold higher sensitivity compared to cell culture [25].
Sampling and logistical support may enable rapid diagnostic results to improve
clinical management and outbreak control in health care settings. New molecular
assays may also improve the detection of antiviral drug-resistance genes and virus
strain subtyping [26].
Figure 4. Serum HI tests confirm seroconversion against influenza A (H1N1) virus. 
Source: adated from [27].
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Clinical spectrum
Influenza virus attachment and replication occurs in ciliated epithelial and goblet cells
in the human airway tracts [28]. After a 2-day incubation period, most cases develop a 5-7
day mild and self-limiting upper respiratory tract infection (URTI) with fever, malaise
and myalgia (Figure 5) [29]. Molecular studies confirm that virus excretion peaks on day
2 and decreases steadily until day 8 or 9 of illness [30–32]. Proinflammatory cytokines
(eg IL-6) are associated with the development of systemic symptoms including fever and
other mild systemic symptoms [33]. 
Influenza infection may be complicated by different types of pneumonia [34–37]. Rare
severe primary viral pneumonia with an acute onset <5 days is poorly defined [34, 35].
Mixed or secondary bacterial and fungal co-infections can emerge after virus-associated
host cell apoptosis of ciliated bronchial epithelial cells [34, 36, 37]. Other complications
include viral lower respiratory tract infection (LRTI), acute respiratory distress
syndrome (ARDS), non-pulmonary organ involvement (e.g. brain, kidneys) and cardio-
vascular events [38, 39].
Figure 5. The natural course of uncomplicated influenza ARTI.
Source: adated from [29].
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Influenza pandemics and seasonal epidemics
Influenza A virus pandemics are the result of antigenic shift and occur ~3 times each
century. Recorded pandemics include 1889 H3N8, 1918 H1N1, 1957 H2N2, 1968 H3N2 and
2009 H1N1 (Figure 6) [40–43]. High mortality rates during the pre-antibiotic era compared to
later pandemics (1957 onwards) underscore the importance of antibiotics and developed
health care systems. Extreme mortality rates during the 1918 pandemic (Figure 7) remain
enigmatic and were probably due to a low pre-existing immunity in humans and high
virulence [44, 45]. Current seasonal epidemics are caused by A/H1N1pdm09, A/H3N2, B/Yama -
gata and B/Victoria viruses. Annual recurrence is caused by frequent antigenic variation
and host immune evasion due to mutations acquired during  replication with a low-fidelity
RNA polymerase. Excess morbidity and mortality is a hallmark of influenza epidemiology
and supports annual virus surveillance and  vaccination of high-risk patients [46].
Figure 6. Influenza pandemics and epidemics. 
Source: adated from [43].
Figure 7. Extreme mortality rates during the 1918 pandemic.
Source: adated from [44].        
A/H1N1
A/H3N8




































Introduction and outline of this thesis |  15
1
Virus surveillance
In 1947, the World Health Organisation (WHO) launched global influenza surveillance
plans ‘to collect and share information on epidemics, strain type and vaccine compo-
sition’ [47]. National surveillance networks weekly assess influenza-like illness reported
by primary health care providers to monitor virus activity and to collect specimens for
virus surveillance (Figure 8) [48]. The WHO now promotes hospital-based surveillance to
assess clinical relevant virus changes to improve prevention and control measures [49— 51].
Annual surveillance is important for the genetic and antigenic characterization of
 circulating influenza viruses to detect new antigenic clusters and subtypes with
pandemic potential. Antigenic clusters that are genetically divergent at key epitopes are
selected for vaccine composition (Figure 9) [52]. Molecular tools are increasingly used
to monitor virus epidemiology, genetic divergence, antiviral drug-resistance and
virulence genes [53].  
Figure 8. The Dutch epidemiology of influenza-like illness during the 2014/2015 season.
Source: adated from [48].
Figure 9. Influenza virus sequence divergence (A) and vaccine strain selection (B, C). 



























• sort all recent strains into clusters.
•find dominant cluster at current time.
• select most recent isolate in cluster.
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Antiviral treatment
Three classes of influenza antiviral agents exist. Adamantanes (amantadine and riman-
tadine) are M2 channel blocking agents that are now obsolete due to poor effectiveness
and common resistance. Neuraminidase inhibitors (NAIs: oseltamivir, peramivir,
zanamivir) are effective agents that block the NA enzyme and prevent host cell viral
release (Figure 10) [54, 55]. A new viral RNA polymerase inhibitor (favipiravir) is not yet
approved but is a promising candidate for influenza combination therapy in patients
who are most at risk [56, 57].
NAIs initiated <48 hours of onset reduce symptoms by ~1 day in healthy adults [58]. NAIs
lower the risk of LRTI in healthy adults but the efficacy is low as the numbers needed to
treat are high [59, 60]. Non-randomized observational studies show that a 5-day NAI
treatment lowers the risk of LRTI and mortality significantly in hospitalized and
immunocompromised patients [61–68]. Severe influenza pneumonia is associated with
higher virus levels compared to mild infection and ratifies an extended NAI treatment
duration [69].
Figure 10. Schematic view and electron micrographs showing continued viral replication during
absence of NAIs (A) and halted viral replication during presence of NAIs (B).  
Source: adated from [54, 55].
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Antiviral resistance and permissive mutations
Influenza resistance mutations can emerge during antiviral treatment [70]. Oseltamivir and
zanamivir resistance mutations may encode highly reduced inhibition (HRI) (>100 fold) or
reduced inhibition (RI) (10-100 fold) IC50 over wild-type virus (Table 1) [71]. NAI resistance
mutations modify the NA active site involved in cleavage of sialic acid binding structures.
Fluorometric assays can measure virus NA activity and inhibition by oseltamivir
carboxylate and zanamivir to determine IC50 fold-changes and phenotypic susceptibility
[72]. NA gene active site modifications were deemed unlikely to emerge due to compromised
viral fitness. In 2007, NA gene H274Y mutated oselta mi vir-resistant A/Brisbane/59/07
(H1N1) virus emerged and circulated dominantly (Figure 11A) [73]. Emergence of permissive
mutations restored deficient NA folding, surface expression and sialic acid affinity and
accommodated the resistance mutation (Figure 11B) [74–76]. Oseltamivir-resistant A (H1N1)
virus became extinct in 2009 and was replaced by wildtype  A(H1N1)pdm09 virus.
Table 1.  Emergence of influenza A virus NAI resistance mutations in the clinical setting. 
HRI, highly induced inhibition; RI, reduced inhibition; S, sensitive.  Source: adated from [71].
Figure 11. Emergence of influenza antiviral resistance (A) and A(H1N1) virus permissive mutations (B).  
Source: adated from [73, 76].
Influenza subtype NA mutation  Phenotype in NA inhibition assays 
Oseltamivir Zanamivir
A(H1N1) H274Y  HRI  S
Q136K S HRI
A(H1N1)dm09 N294S HRI S
H274Y HRI S
I222R RI RI
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High-risk patients
Influenza-infected high-risk patients are more prone to develop severe complications and
adverse outcomes [77]. High-risk patients include the elderly, aged ≥65 years (Figure 12) and
patients with pre-existing chronic cardiac or pulmonary conditions, cardiovascular
disease, diabetes mellitus, renal disease, immunosuppression, and obesity (Table 2) [78, 79].
During the 2009 H1N1 pandemic, extreme obesity (BMI ≥40) was recognized as a new inde -
pendent risk factor for the development of influenza  complications [80]. Elderly people aged
≥65 years are at risk to develop influenza complications due to frequent co-morbidities and
a functional decline of the adaptive immune system (immunosenescence). The annual
influenza mortality rate is estimated at a minimum of 1 in 1500 elderly persons [81]. Nursing
home residents are particularly at risk to develop associated morbidity and mortality [82].
Frequent severe influenza outbreaks in nursing homes  demand effective preventive and
control measures and early diagnostics to guide early clinical management [83].
Figure 12. Age distribution of seasonal human influenza mortality in the human population.
Source: adated from [78].
Table 2. Increased mortality in high-risk patients with influenza A (H1N1)pdm09 virus infection.      
















<1 1-4 5-14 15-24 25-44 45-64 65+
Charateristic
Nonsevere outcome,
no. (%) of patients
n = 1171
Death
No. (%) of patients
n = 72 RR (95% CI) *
Pre-existing heart disease 80/1049              (7.6) 16/65                (24.6) 3.5                (2.1–5.9)
Diabetes mellitus 82/1047              (7.8) 13/65                (20.0) 2.7                (1.5–4.7)
Renal disease 51/1044              (4.9) 7/64                   (10.9) 2.2                (1.1–4.7)
Immunosuression 93/1041             (8/9) 17/64                (26.6) 3.3                (2.0–5.5)
Lung disease (including asthma) 309/738           (41.9) 30/52                (57.7) 1.8                (1.1–3.1)
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Vaccination
Influenza viruses frequently mutate and evolve into phylogenetic and antigenic
variants [84]. Annual subtype dominance varies but A (H3N2) viruses appear more
common due to more common mutations and antigenic variation (Figure 13 A, B).
Multiple observational studies show that vaccines lower the risk of influenza infection,
hospitalization and mortality in high-risk patients but confirmatory randomized
controlled trials are lacking [85–89]. Vaccines lower the risk of laboratory confirmed
influenza in community-dwelling elderly [87–89], and of pneumonia and associated
mortality in institutionalized elderly [90]. Serum HI titers ≥40 after vaccination
provide ~50% (up to 70%) clinical protection against homologous virus infection and
are traditionally considered seroprotective (Table 3) [91, 92]. 
Figure 13. Influenza virus evolution and genetic changes (A) with subtype dominance (B).  
Source: adated from [84].
Table 3. Relationship between serum HI titers and influenza virus infection in volunteers.     
Source: adated from [92].
A B
Titre of serum HI antibody to A/Scotland/74 (H3N2) virus
≤10 20-30 40-60 80-120 160 Total
Number of volunteers 19 9 7 16 24 75
Number of infected * 14 3 2 1 1 21
Infection (%) 74 33 29 6 4 28
* Infection roved by vrus isolation 3 days after infection and/or a fourfold or greater rise in serum HI antibody
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Host immune responses
Innate and adaptive immune responses are important for influenza infection con trol (Figure
14, 15) [93, 94]. Host Toll-like receptors, RIG-I receptors and NLRP3 recog nize virus pathogen-
associated molecular patterns (PAMPs) and activate interferon (IFN) responses [93, 95].
Infected epithelial cells produce CCL2 that attracts monocytes, natural killer (NK) cells and
memory T-cells. T cells, macrophages, NK cells, neutrophils limit viral spread by destruction
of infected cells or phagocytosis and produce proinflammatory cytokines (e.g. IL-6, TNF-α).
Adaptive immune responses and memory development result from antigen presentation
by dendritic cells [93, 96]. Plasma B cells produce virus-specific antibodies whereas T cells
regulate immunity and virus-infected cell killing. The precise role of innate and adaptive
host immune responses in determining symptoms and viral clearance is unclear.
Figure 14. Induction of influenza humoral and cell-mediated adaptive immunity.
Source: adated from [93].
Figure 15. Host immune responses during influenza virus infection. 
Source: adated from [94].
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Hematology-oncology patients with influenza
Influenza-infected hematology-oncology patients are more likely to develop LRTI com pared
to other immunocompromised patients [97]. Risk factors for viral LRTI include age, lack of
(early) antiviral treatment, profound lymphopenia and hema topoietic stem cell transplan-
tation (HSCT) donor mismatch [98, 64–66]. Severe immu nodeficiency is associated with high
level prolonged virus excretion and with frequent development of resistant virus during
antiviral treatment (Figure 16) [99–103]. Hema tology-oncology patients develop a wide
clinical spectrum ranging from mild to severe virus-associated symptoms [104, 105]. Adverse
outcomes often occur early after HSCT [98]. Immune monitoring studies are awaited to
elucidate the role of host immune responses in determining virus-associated symptoms and
viral clearance among an expanding numbers of HSCT patients (Figure 17) [106, 107].
Figure 16. Influenza virus levels in severe () vs moderate () immunodeficient patients.
Source: adated from [99].
Figure 17. Rising numbers of hematology-oncology patients in Europe from 1998 to 2013. 
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Outline of this thesis
This thesis focuses on a variety of subjects related to the molecular diagnosis and
clinical consequences of seasonal and pandemic influenza virus infections in a wide
range of patients. The main objectives were (1) to evaluate influenza real-time PCR
diagnostic methods and clinical aspects of seasonal and pandemic influenza virus
infection, (2) to investigate the applicability and accuracy of mass spectrometry-based
molecular techniques and real-time PCR to detect influenza virus resistance and
virulence genes, and (3) to correlate the role of different host immune responses with
virus-associated symptoms and viral clearance in immunocompromised patients with
prolonged influenza virus excretion. 
The studies described in this thesis are presented in the following chapters:
Chapter 2 describes the relative incidence of respiratory virus infections in children
presenting to the hospital and virus-specific clinical correlations in young children.             
In chapter 3, two children with fatal influenza virus-associated pneumonia, encephalo -
pathy and multiple organ failure are described and we performed molecular and patho-
logical studies to confirm or refute virus dissemination and replication in other organs.
Chapter 4 is a study that compared influenza immunoassay and PCR methods on
nursing homes specimens and evaluated the efficacy of Public Health Service outbreak
team support.
Chapter 5 describes the clinical manifestation and antiviral resistance development in
immunocompromised patients with ≥14 days prolonged influenza virus excretion.
In chapter 6, a phylogenetic relationship was performed among oseltamivir-resistant
influenza A (H1N1) viruses in a patient cluster to assess nosocomial virus transmission.         
Chapter 7 describes the detection of influenza virus resistance and virulence markers in
routine clinical specimens using mass spectrometry-based comparative sequence analysis.
Chapter 8 describes the role of host immune responses in determining influenza virus-
associated symptoms and viral clearance in hematology-oncology patients. 
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Abstract
Background: The relative incidence and clinical impact of individual respiratory
viruses remains unclear among children presenting to the hospital emergency depart -
ment with acute respiratory tract infection (ARTI).
Methods: During two winter periods, respiratory virus real-time multiplex PCR results
were evaluated from children (<18 years) presenting to the emergency department of a
tertiary referral hospital with ARTI that had been sampled within 48 hours of hospital
presentation. In an attempt to identify virus-specific distinguishing clinical features,
single virus infections were correlated with presenting signs and symptoms, clinical
findings and outcomes using multivariate logistic regression.
Results: In total, 274 children with ARTI were evaluated and most were aged <3 years
(236/274, 86%). PCR detected respiratory viruses in 224/274 (81.8%) children and included
162 (59%) single and 62 (23%) mixed virus infections. Respiratory syncytial virus (RSV) and
human rhinovirus (HRV) single virus infections were common among children aged
<3 years, but proportional differences compared to older children were only significant
for RSV (95% CI 1.3–15). Clinical differentiation between viral ARTIs was not possible due
to common shared presenting signs and symptoms and the high frequency of mixed
viral infections. We observed virus-associated out come differences among children
aged <3 years. Oxygen treatment was associated with RSV (OR 3.6) and inversely corre-
lated with FLU (OR 0.05). Treatment with steroids (OR 3.4) or bronchodilators (OR 3.4)
was associated with HRV. Severe respiratory complications were associated with HRV
(OR 3.5) and inversely correlated with RSV (OR 0.24).
Conclusions: Respiratory viruses are frequently detected in young children presenting
to the hospital emergency department with ARTI and require PCR diagnosis since
presenting signs and symptoms are not discriminant for a type of virus. RSV and HRV
bear a high burden of morbidity in the pediatric clinical setting.
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Background
Children suffer through multiple episodes of viral acute respiratory tract infection
(ARTI) annually and symptoms range from common mild upper respiratory illness to
lower respiratory tract infection (LRTI) [1,  2]. Large-scale studies during the past decades
were unable to provide accurate virus-specific clinical correlations due to the low sensi-
tivity of viral culture and immunofluorescence techniques and inability of these
diagnostic methods to detect non-culturable or mixed viral  infections [1,  3]. The routine
implementation of multiplex PCR in recent years has allowed for sensitive and accurate
identification of single and mixed viral infections [4,  5]. The burden of individual respi-
ratory viruses remains unclear among different pediatric age-groups in the clinical
setting. Recent molecular population-based studies show that viral ARTIs exceed 21% of
pediatric emergency department visits during the seasonal influenza winter season
and annual  hospitalization rates exceed 1.5 per 100 children aged <3 years [6–8]. These
findings suggest a high burden of viral ARTI in young children. The burden of viral
respiratory pathogens in children is under estimated since human rhinovirus (HRV)
infections were not evaluated in these studies. Recent clinical studies have included
HRV molecular diagnostics, but  interpretation of virus-associated correlations is
hampered by age- and symptom-related enrollment differences [9,  10] or by sampling
during the 2009 influenza pandemic [11,  12]. This study assessed the relative incidence of
respiratory virus infections in children presenting to the emergency department of a
tertiary hospital with ARTI during two winter seasons and evaluated virus-specific
clinical correlations in young children.
Methods
Study design and patient populations. This retrospective cohort study included
all children aged <18 years presenting to the emergency department of Leiden University
Medical Center (LUMC) during the 2006 and 2007 winter seasons (November–April) with
ARTI who were sampled within 48 hours of hospital presentation. The LUMC is a tertiary
referral hospital for the south-western part of the Netherlands covering a population of
approximately 2 million inhabitants. Clinical diagnosis of ARTI was made by the
attending physician. Routine diagnostic specimens were prospectively analyzed by
respiratory virus multiplex PCR to evaluate the relative incidence of respiratory viruses
among different pediatric age-groups (children aged <3 years and children aged 3–17
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years). Structured medical records of children aged <3 years with single virus infections
(RSV, HRV, FLU or Other) were evaluated for baseline characteristics, presenting signs
and symptoms and clinical outcomes.
Respiratory specimens and molecular diagnostics. Qualified medical personnel
obtained diagnostic respiratory specimens and a single specimen was evaluated for each
child sampled within 48 hours of hospital presentation. Respiratory specimens included
nasopharyngeal washes, throat swabs, nasal swabs, sputum or tracheal aspirates. Nucleic
acid was extracted by using a MagnaPure LC total nucleic acid kit (Roche Diagnostics,
Mannheim, Germany) as described [4]. A fixed amount of equine arteritis virus served as
an RNA internal control and phocid herpesvirus was used as a DNA internal control.
Respiratory virus multiplex PCR detected respiratory syncytial virus (RSV), human
rhinovirus (HRV), influenzavirus (FLU) A/B, parainfluenzavirus (PIV) 1/2/3/4, human
metapneumovirus (HMPV), human coronavirus (HCoV) 229E/NL63/OC43, and adenovirus
(HAdV) in multiple tubes as described [4]. Primers, probes and amplification methods of
the multiplex PCR used in this study are described in reference 4 for laboratory 2. In a
pilot run during the 2007 winter season, we performed additional real-time PCR analysis
of HCoV HKU1, Mycoplasma pneumoniae and Chlamydophila pneumoniae [4]. During this
pilot run, we performed additional analysis of human bocavirus (HBoV) by real-time PCR
amplification of a 138-bp fragment of the NS1 gene as described by others [13].
Ethics. The study was conducted in accordance with ethical principles expressed in the
World Medical Association Declaration of Helsinki. The study procedures complied with
legal and regulatory standards and clinical data was obtained by following professional
codes of conduct. All necessary precautions were taken to prevent identification of any
child included in the study. The Medical Ethics Committee (MEC) of Leiden University
Medical Center reviewed the study protocol (C14.128) and final version of the manuscript
and confirms that the study is based on clinical data collected in the context of routine
clinical practice. For this retrospective analysis of routine clinical data the committee
declares that no formal ethical approval and written informed consent is needed. 
Study procedure – viral distribution. Routine diagnostic PCR results from all eligible
children were analyzed. Distribution of RSV, HRV, FLU and Other single virus infections
was depicted by age-groups (young children aged <3 years and children aged 3–17 years).
PIV, HMPV, HAdV and HCoV were aggregated into a distinct group (Other) due to small
numbers and to enable more accurate comparative virus-associated correlations.
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Study procedure – presenting signs and symptoms. The attending physician
recorded signs and symptoms of young children aged <3 years using structured medical
records. Presenting signs and symptoms manifesting within 48 hours of hospital presen-
tation of children with RSV, HRV, FLU or Other single virus infections were evaluated.
Virus-associated symptoms were compared and included fever >38.5 °C, cough, rhinitis,
pharyngitis, wheezing, crepitation, dyspnea or tachypnea. The clinical presence of chest
wall retractions, nasal flaring, moaning or labored breathing were used to define
dyspnea World Health Organization clinical diagnostic criteria defined tachypnea
among children aged <2 months (≥60 breaths per minute, bpm), aged 2 to 12 months (≥50
bpm) and aged ≥12 months (≥40 bpm). 
Study procedure – outcomes. The attending physician recorded outcomes of children
aged <3 years with RSV, HRV, FLU and Other single virus infections. We evaluated
laboratory and pulmonary imaging findings that were obtained within 96 hours of
hospital presentation and adverse outcome manifestations (hospital admission, severe
respiratory complications, mortality) that were recorded within ≤7 days of hospital
presentation. Laboratory findings included C-reactive protein (CRP) and white blood cell
count (WBC). We evaluated cut-offs that would indicate absence of serious bacterial infec-
tions (CRP <35 mg/l; WBC <15 x109/L) [14,  15]. We compared bacteriology results that were
obtained by PCR (atypical bacteria) or from routine cultures from non-sterile (urine,
sputum) and sterile sites (blood, cerebrospinal fluid). Pulmonary imaging findings
were assessed for signs of LRTI (radiologic presence of alveolar or peribronchial infil-
trates, interstitial opacities, and hyperinflation). Supplemental treatments included
bronchodilators, steroids, oxygen supplementation and antibiotics. Oxygen supplemen-
tation was provided during sustained oxygen saturation ≤92% or during dyspnea with
abnormal PCO2 levels. Adverse outcomes included hospital admission, development of
severe respiratory complications and all-cause mortality ≤7 days of hospital presentation.
Severe respiratory complications were defined as apnea, respiratory intubation and
Apparent Life Threatening Events (ALTE). ALTE was defined as an acute change in an
infant’s breathing behavior perceived as possibly life threatening by the child’s caretaker.  
Statistical analysis. Statistical analyses were performed using SPSS software version
20.0 (SPSS, Chicago, IL). Continuous variables were presented as mean or median (with
range) and categorical variables as frequencies (with percentages). Mann Whitney U-
test and Kruskal Wallis test were used as non-parametric tests to compare age (months)
between 2 or more groups, because of non-normally distributed data. Chi square was
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performed to compare categorical variables between 2 groups. Logistic regression
analysis compared categorical variables between virus groups including presenting
signs and symptoms, diagnostic, treatment and outcome findings. Multivariate analyses
adjusted for age, gender and relevant history or chronic underlying disorders (stepwise).
A 2-sided value of P <0.05 was considered significant.
Results
Patient enrollment and viral etiology. During two winter seasons, we enrolled
274 children presenting to the emergency department with ARTI and sampled within
48 hours of hospital presentation. The majority of children were aged <3 years (236/274,
86%) compared to older children aged 3–17 years (38/274, 14%). Multiplex PCR detected
respiratory viruses in 82% (224/274) of all children and included single virus infections
(162 of 224, 72%) and mixed viral infections (62 of 224, 28%) (Figure 1). Single virus
 infections were caused by RSV (69 of 224, 31%), HRV (53 of 224, 24%), FLU (16 of 224, 7%)
and Other (24 of 224, 11%). In a pilot run among a total 131 children during the
2007 winter season, PCR yielded HBoV (7%) and HCoV HKU1 (1%), but no Mycoplasma
pneumoniae and Chlamydophila pneu moniae. HBoV- and HCoV HKU1-associated clinical
findings were not evaluated due to a rare occurrence of single virus infections (n = 4
HBoV; n = 0 HCoV HKU1) and due to incomplete data (single season). 
Figure 1. Viral etiologies of 274 children with ARTI presenting to the emergency department of a
tertiary referral hospital.
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Figure 2. Distribution of single respiratory virus infections among different pediatric age groups.
Respiratory virus distribution. The distribution of single virus infections among
different age groups was evaluated in an attempt to establish virus-associated clinical
correlations. Mixed viral infections were not analyzed due to the small sample size and
the difficulty to establish clinical relevance. Single virus infections were common
among young children aged <3 years (144 of 236, 61%) compared to older children (18 of
38, 47%) but these proportional differences were not statistically significant (Figure 2).
RSV and HRV were more common among children aged <3 years compared to older
children, but proportional differences were only significant for RSV (28% vs 7.9%; 95%
CI 1.3–15). In contrast, young children were less common infected with Other single
viruses (including PIV, HMPV, HAdV or HCoV) compared to older children (7.2% vs 18%;
95% CI 0.13–0.90). FLU single virus infections were uncommon in both age groups with
a similar low prevalence (range, 5 to 11%). 
Virus-specific clinical correlations – baseline characteristics. Evaluation of baseline
characteristics was limited to children aged <3 years with single virus infections (RSV,
HRV, FLU, Other) with clinical data available. We included demographics (sex, age)
and relevant history encompassing prematurity at birth (gestational age <37 weeks),
bronchial hyperreactivity (bronchoconstriction in response to stimuli) and underlying
pulmonary, cardiovascular and immunodeficiency disorders. Base-line characteristics
were equally distributed among virus groups, except for a male predominance (Table 1)
among children with HRV vs FLU (73% vs 36%; 95% CI 1.2–19). Proportional differences
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Table 1.  Baseline characteristics of children aged <3 years with single respiratory virus infections.
Figure 3. Signs and symptoms of 138 children aged <3 years presenting to the emergency
department of a tertiary referral hospital with single virus ARTI. 
The roortions of resenting signs and symtoms were comared between virus grous using logistic
regression analysis and stewise multivariate adjustment for demograhics and relevant clinical history.
Significant roortional differences (P <0.05) between virus grous are deicted and include fever (FLU vs











Children <3 y with single virus ARTI 
Total included 144 66 49 12 17
Analysis of signs and symtoms (data available) 138 64 46 11 17
Analysis of clinical outcomes (data available) 123 53 44 11 15
Demographics (analysis of clinical outcomes)
Male 76 (62) 30 (57) 32 (73) $ 4 (36) $ 10 (67)
Mean age, months [range] 8 [0 – 35] 7 [0 – 35] 7 [0 – 24] 10 [1 – 26] 7 [0 – 35]
Median age, months [range] 4 [0 – 35] 3 [0 – 35] 4 [0 – 24] 9 [1 – 26] 8 [0 – 33]
Clinical history (analysis of clinical outcomes)
Prematurity at birth   11 (9) 6 (11) 3 (7) 1 (9) 1 (7)
History of BHR     12 (9) 5 (9) 5 (11) 1 (9) 1 (7)
hronic ulmonary disorder    2   (2) 0 2 (5) 0 0
hronic cardiovascular disorder     12 (10) 3 (6) 6 (14) 1 (9) 2 (13)
hronic immunodeficiency disorder     5   (4) 0 2 (5) 1 (9) 2 (13)
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Virus-specific clinical correlations – signs and symptoms. Presenting signs and
symptoms were compared among 138 children aged <3 years with single virus infections
and clinical data available (Table 1, Figure 3). Six children were previously excluded from
comparative analyses due to incomplete documentation. Children aged 3–17 years were
not evaluated due to small numbers and age-related confounding differences.
Multivariate analyses adjusted for possible confounders including age and sex, and
stepwise for relevant underlying disorders. Significant virus-associated presenting signs
and symptoms (Figure 3) included fever (FLU vs RSV, P = 0.01; FLU vs HRV, P = 0.01),
cough (RSV vs FLU, P = 0.02; RSV vs Other, P = 0.03), crepitation (RSV vs HRV, P = 0.02),
dyspnea and tachypnea (RSV vs FLU, P = 0.04).
Virus-specific clinical correlations – clinical outcomes.  Clinical outcomes were
compared among 123 children aged <3 years with single virus infections and clinical
data available (Table 1, Table 2). A total of 21 children were previously excluded from
comparative analyses due to incomplete documentation or hospital transfer without
follow-up data. Excluded cases were equally distributed among virus groups (Table 1).
High levels of CRP (≥35 mg/l) or WBC (≥15 x 109/L) and antibiotic treatment were equally
distributed among virus groups and suggested no differences in potential serious
bacterial infections. Bacterial cultures and PCRs were often negative and were equally
distributed among individual virus infections. This supports the assumption that there
were no differences in potential serious bacterial infections among virus groups.
Hospital admission (~80%) was equally distributed and fortunately there was no
mortality. Overall and individual comparisons were made among children with RSV,
HRV, FLU and Other single virus infections (Table 2) following multivariate adjustment
for possible confounders. 
RSV. Overall, RSV infection was associated with supplemental oxygen requirement
(OR 3.6) and inversely correlated with severe respiratory complications (OR 0.24).
Individual comparisons revealed that RSV was associated with supplemental oxygen
requirement compared to FLU (OR 26) and Other (OR 4.2).
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Table 2. Outcomes associated with single respiratory virus infections in children <3 years. 
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RP ≥ 35 mg/L 28/81 (35) 11/32 (34) 11/29 (38) 2/9 (22) 4/11 (36) NS
WB ≥ 15 x109/L 27/80 (34) 11/32 (34) 11/28 (39) 2/9 (22) 3/11 (27) NS
Bacteriology NS
PR atyical  bacteria 0/10 (0) 0/2 (0) 0/4 (0) 0/1 (0) 0/3 (0) NS
ulture, sterile site 2/45 (4) 0/15 (0) 1/17 (6) 0/7 (0) 1/6 (17) NS
ulture, non-sterile site 1/19 (5) 0/7 (0) 0/8 (0) 0/1 (0) 1/3 (33) NS
Pulmonary imaging
LRTI# 31/63 (37) 15/24 (63) 10/25 (40) 3/6 (50) 3/8 (38) NS
Treatment
Antibiotics 50/122 (41) 24/53 (45) 17/43 (40) 3/11 (27) 6/15 (40) NS
Bronchodilators 31/113 (27) 12/48 (25) 15/39 (38) 2/11 (18) 2/15 (13) HRV vs Other 7.0 (1.2-42) .03
HRV overall 3.0 (1.2-7.8) .02
Steroids 26/117 (22) 8/52 (15) 13/39 (33) 2/11 (18) 3/15 (20) HRV vs RSV 3.5 (1.2-11) .03
HRV overall 3.4 (1.2-9.3) .02
Oxygen theray 67/118 (57) 38/52 (73) 22/41 (54) 1/10 (10) 6/15 (40) RSV vs FLU 26 (3.0-225) < .01
RSV vs Other 4.2 (1.3-14) .02
HRV vs FLU 11 (1.2-97) .03
RSV overall 3.6 (1.6-8.0) < .01
FLU overall .05 (.01-.40) < .01
Adverse outcome
Hosital admission 99/123 (80) 46/53 (87) 33/44 (75) 8/11 (73) 12/15 (80) NS
Severe resiratory comlication 15/123 (12) 3/53 (6) 9/44 (20) 1/11 (9) 2/15 (13) HRV vs RSV 5.0 (1.2-21) .03
HRV overall 3.5 (1.0-11) .04
RSV overall .24 (.06-.92) .04
Anea 5/123 (4) 1/53 (2) 4/44 (9) 0/11 (0) 0/15 (0) NS
Intubation 7/123 (6) 1/53 (2) 5/44 (11) 0/11 (0) 1/15 (7) NS
ALTE 6/123 (5) 1/53 (2) 3/44 (7) 1/11 (9) 1/15 (7) NS
Mortality ≤ 7 days 0/123 (0) 0/53 (0) 0/44 (0) 0/11 (0) 0/15 (0) NS
ARTI, Acute Respiratory Tract Infection, CRP, C-reactive protein; WBC, White Blood Cell count; LRTI, lower respiratory tract infection; ALTE, Apparent Life
Threatening Events; NS, not significant.
#   LRTI was defined as radiologic presence of alveolar infiltrates, interstitial opacities, peribronchial infiltrates or hyperinflation.
$  Multivariate correction for sex, age and underlying disease (forward stepwise adjustment) using logistic regression analysis.
HRV. Overall, HRV infection was associated with bronchodilator therapy (OR 3.0), steroid
treatment (OR 3.4) and severe respiratory complications (OR 3.5). Individual comparisons
revealed that HRV was associated with bronchodilator therapy compared to Other (OR
7.0), steroid treatment compared to RSV (OR 3.5), supplemental oxygen requirement
compared to FLU (OR 11) and severe respiratory  com plications (apnea, respiratory
intubation or ALTE) compared to RSV (OR 5.0). HRV subtyping was not performed and
therefore specific subtypes could not be associated with clinical outcome. 
FLU. Overall, Flu infection was inversely correlated with supplemental oxygen require -
ment (OR 0.05). Individual comparisons revealed no FLU specific outcome asso ciations.
Discussion
This study confirmed a frequent viral etiology among 82% (224 of 274) of children aged
<18 years presenting to the emergency department of a tertiary hospital with ARTI.
These findings add to a growing body of literature on the epidemiology and virus-
associated clinical features in the clinical setting [6–12]. 
The high detection rate of respiratory viruses using multiplex PCR was similar to
 previously published rates exceeding 80% in the pediatric clinical setting [10,  11]. Much
lower detection rates (range 58% – 67%) in a few other studies are likely due to age-
and symptom-related enrollment differences or due to sampling during non-winter
seasons [9,  12]. A high rate of mixed viral infections in this study (23%) is similar to
findings in other studies (range 14% – 30%) [9–11]. 
Children presenting to the hospital emergency department with ARTI and sampled
within 48 hours were predominantly aged <3 years (236 of 274, 86%). HRV and RSV single
virus infections were common among children aged <3 years, but proportional differ-
ences compared to older children were only significant for RSV (95% CI 1.3–15). Previous
studies report a similar predominance of RSV among young children in the clinical
setting [7,  8,  10] but reports on HRV age-distribution are mixed [10,  16]. FLU cases were often
young children (n = 12) compared to older children (n = 4) but the small numbers and the
lack of a population-based design restrict firm epidemiologic  con clusions. 
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Viral ARTI signs and symptoms are widely presumed to be aspecific but confirmation of
this assumption is lacking. This study confirmed that viral ARTI presenting signs and
symptoms are aspecific by comparative statistical analysis among children aged <3 years
with single virus infections. Fever was often associated with influenza (FLU vs RSV,
P = 0.01; FLU vs HRV, P = 0.01) and cough was often associated with RSV (RSV vs FLU,
P = 0.02; RSV vs Other, P = 0.03). Unfortunately, these and other findings were insufficient
to differentiate between individual viral ARTIs due to common shared signs and symptoms
among viruses and the high frequency of mixed viral infections [9]. A febrile disease with
ARTI symptoms was observed among ≥25% of total viruses infections, therefore influenza-
like illness required PCR confirmation to establish FLU diagnosis [17,  18]. 
Virus-specific comparative outcome analysis among children aged <3 years with single
virus infections unveiled clinical outcome similarities (Table 2). Laboratory infection
parameters (CRP, WBC), pulmonary imaging LRTI findings and antibiotic use were
similar among virus groups. The findings contrast with a previous study which reported
high CRP levels, elevated leukocyte counts and frequent antibiotic use during HRV [10].
In this study, children with RSV often received antibiotics (45%). Previous studies show
that rapid confirmation of RSV can limit antibiotic use [19,  20], but antibiotic stewardship
guided by respiratory virus PCR results may be difficult to implement [21]. 
Relevant virus-specific outcome differences include supplemental oxygen treat ment
requirement (RSV), steroid and bronchodilator treatment (HRV) and development of
severe respiratory complications (HRV). Supplemental treatments with corticosteroids
and bronchodilators were remarkably associated with HRV. There is insufficient
evidence on the benefit of corticosteroids or bronchodilators during viral LRTI and most
guidelines do not recommend the routine use for cases of RSV LRTI [22]. However, corti-
costeroids may improve HRV-induced wheezing and bronchodilators may be effective
for individual children experiencing LRTI with underlying reactive airway disease. This
may explain why corticosteroids and bronchodilators were more commonly provided
to children with HRV. Young children presenting to the hospital emergency department
with the combined symptoms of cough, pulmonary crepitation and oxygen-dependent
viral LRTI were more likely to be infected with RSV than with other viruses as reported
by others [12,  23]. With the knowledge that RSV is more often associated with oxygen-
dependent viral LRTI, it would seem counter-intuitive that HRV (and not RSV) is
associated with more severe respiratory complications (Table 2). HRV often causes mild
symptoms, but the findings of this and other studies suggest that the occurrence of
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severe HRV respiratory complications may be underestimated [24,  25]. In this study, FLU
infection was inversely correlated with supplemental oxygen treatment compared to
other infections as described by others [26]. We emphasize that the low number of FLU
cases does not allow for any firm conclusions on this matter. Previous studies suggest
that FLU manifestations may be relatively mild among young children presenting to the
hospital during seasonal influenza, but rare life-threatening events and severe cases of
concomitant bacterial pneumonia do occur [12,  27]. 
Limitations. Children were evaluated at a tertiary care setting and this possibly limits
the validity of virus-specific clinical correlations in other settings. The retrospective
design of the study and evaluation of the patients by different attending physicians may
have introduced a reporting bias. The inclusion of children sampled within 48 hours of
hospital presentation may have introduced a selection bias towards younger patients
due to a more cautious clinical and diagnostic approach of parents and pediatricians in
that age group [28]. This could explain why the majority of children included in this
study were aged <3 years (236/274, 86%). The respiratory specimens were of different
types (including nasopharyngeal washes, throat swabs, nasal swabs, sputum or tracheal
aspirates) which could have bearing on the sensitivity of the PCR for the various viruses
and thus their relative frequency. The number of children with viral ARTI is an under-
estimation since our multiplex PCR did not detect HBoV, HCoV HKU1, human influenza
C virus and enteroviruses that may cause viral respiratory infections. Molecular differ-
entiation of HRV and enteroviruses is difficult and the HRV assay used in this study
cross-reacts with a few enteroviruses that are associated with respiratory infections.
This variation in HRV types may explain severe HRV infections and emphasizes that
future studies should elucidate the specific role of HRV and enteroviruses using
molecular subtyping. In this study, multiple comparisons were performed which can
lead to more type I errors (more false positives) since 5% of the comparisons have uncor-
rected P values <0.05. Statistical adjustment of confidence intervals (e.g. Bonferroni
corrections) can be applied to reduce incorrect rejection of true null hypotheses and to
lower type I errors, but these corrections can increase the type II error (more false
negatives) and lead to interpretation errors [29]. In this observational study, no adjust-
ments were made for multiple comparisons in an attempt to find novel virus-specific
clinical correlations. This approach is intended for hypothesis generation and not for
hypothesis testing. Future prospective studies using improved standardized study
protocols are therefore awaited to confirm virus-associated clinical findings and for
hypothesis testing. 
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Conclusions. This study confirmed that a viral agent is frequently found in young
children with ARTI presenting to the pediatric emergency department of a tertiary
referral hospital. Molecular diagnostics are required to confirm respiratory virus infec-
tions since presenting symptoms could not discriminate between the viruses. RSV and
HRV infections bear the highest burden of morbidity in the pediatric clinical setting.
Competing interests
The authors declare that they have no competing interests. There was no financial
support. 
Acknowledgements
Ron Wolterbeek (Department of Medical Statistics and Bioinformatics) provided
valuable statistical advice. We thank Pulak Goswami for language editing support.
46 |  hater 2
Molecular diagnosis of resiratory virus infections in children |  47
References
Monto AS. Studies of the community and1.
family: acute respiratory illness and infection.
Epidemiol Rev 1994; 16: 351–73.
Yorita KL, Holman RC, Sejvar JJ, Steiner CA,2.
Schonberger LB. Infectious disease hospitaliza-
tions among infants in the United States.
Pediatrics 2008; 121: 244–52.
Jacobs JW, Peacock DB, Corner BD, Caul EO,3.
Clarke SK. Respiratory syncytial and other
viruses associated with respiratory disease
in infants. Lancet 1971; 1: 871–6.
Loens K, van Loon AM, Coenjaerts F, et al.4.
GRACE Study Group. Performance of different
mono- and multiplex nucleic acid amplification
tests on a multi-pathogen external quality
assessment panel. J Clin Microbiol 2012; 50: 977–
87.
Freymuth F, Vabret A, Cuvillon-Nimal D, et al.5.
Comparison of multiplex PCR assays and
conventional techniques for the diagnostic of
respiratory virus infections in children
admitted to hospital with an acute respiratory
illness. J Med Virol 2006; 78: 1498–504.
Forster J, Ihorst G, Rieger CH, et al. Prospective6.
population-based study of viral lower respi-
ratory tract infections in children under 3
years of age (the PRI.DE study). Eur J Pediatr
2004; 163: 709–16.
Iwane MK, Edwards KM, Szilagyi PG, et al. New7.
Vaccine Surveillance Network. Population-
based surveillance for hospitalizations
associated with respiratory syncytial virus,
influenza virus, and parainfluenza viruses
among young children. Pediatrics 2004; 113:
1758–64.
Bourgeois FT, Valim C, Wei JC, McAdam AJ,8.
Mandl KD. Influenza and other respiratory
virus-related emergency department visits
among young children. Pediatrics 2006; 118:
e1–8.
Cilla G, Onate E, Perez-Yarza EG, Montes M,9.
Vicente D, Perez T. Viruses in community-
acquired pneumonia in children aged less than
3 years old: high rate of viral co-infection.
J Med Virol 2008; 80: 1843–9. 
Garcia-Garcia ML, Calvo C, Pozo F, Villadangos10.
PA, Perez-Brena P, Casas I. Spectrum of
respiratory viruses in children with
community-acquired pneumonia. Pediatr Infect
Dis J 2012; 31: 808–13.
Laurent C, Dugue AE, Brouard J, et al. Viral11.
epidemiology and severity of respiratory
infections in infants in 2009: a prospective
study. Pediatr Infect Dis J 2012; 31: 827–31.
Pierangeli A, Scagnolari C, Selvaggi C, et al.12.
Virological and clinical characterization of
respiratory infections in children attending
an emergency department during the first
autumn-winter circulation of pandemic A
(H1N1) 2009 influenza virus. Clin Microbiol
Infect 2012; 18: 366–73.
Allander T, Tammi MT, Eriksson M, Bjerkner A,13.
Tiveljung-Lindell A, Andersson B. Cloning of
a human parvovirus by molecular screening of
respiratory tract samples. Proc Natl Acad Sci U
S A 2005; 102: 12891–6.
Pulliam PN, Attia MW, Cronan KM. C-reactive14.
protein in febrile children 1 to 36 months of age
with clinically undetectable serious bacterial
infection. Pediatrics 2001; 108: 1275–9.
2
Yo CH, Hsieh PS, Lee SH, et al. Comparison of15.
the test characteristics of procalcitonin to
C-reactive protein and leukocytosis for the
detection of serious bacterial infections in
children presenting with fever without source:
a systematic review and meta-analysis.
Ann Emerg Med 2012; 60: 591–600. 
Miller EK, Lu X, Erdman DD, et al. New Vaccine16.
Surveillance Network. Rhinovirus-associated
hospitalizations in young children. J Infect Dis
2007; 195: 773–81.
Wallace LA, Collins TC, Douglas JD, McIntyre S,17.
Millar J, Carman WF. Virological surveillance of
influenza-like illness in the community using
PCR and serology. J Clin Virol 2004; 31: 40–5. 
Schnepf N, Resche-Rigon M, Chaillon A, et al.18.
High burden of non-influenza viruses in
influenza-like illness in the early weeks of
H1N1v epidemic in France. PLoS One 2011; 6:
e23514.
Woo PC, Chiu SS, Seto WH, Peiris M. Cost-effec-19.
tiveness of rapid diagnosis of viral respiratory
tract infections in pediatric patients.
J Clin Microbiol 1997; 35: 1579–81.
Purcell K, Fergie J. Concurrent serious bacterial20.
infections in 2396 infants and children
hospitalized with respiratory syncytial virus
lower respiratory tract infections. Arch Pediatr
Adolesc Med 2002; 156: 322–4.
Wishaupt JO, Russcher A, Smeets LC, Versteegh21.
FG, Hartwig NG. Clinical impact of RT-PCR
for pediatric acute respiratory infections:
a controlled clinical trial. Pediatrics 2011; 128:
e1113–20.
Tregoning JS, Schwarze J. Respiratory viral22.
infections in infants: causes, clinical
symptoms, virology, and immunology.
Clin Microbiol Rev 2010; 23: 74–98.
Hall CB, Weinberg GA, Iwane MK, et al.23.
The burden of respiratory syncytial virus
infection in young children. N Engl J Med 2009;
360: 588–98.
Iwane MK, Prill MM, Lu X, et al. Human24.
rhinovirus species associated with hospitaliza-
tions for acute respiratory illness in young US
children. J Infect Dis 2011; 204: 1702–10.
Asner SA, Petrich A, Hamid JS, Mertz D,25.
Richardson SE, Smieja M. Clinical severity of
rhinovirus/enterovirus compared to other
respiratory viruses in children. Influenza Other
Respir Viruses 2014; 8: 436–42.
Hite LK, Glezen WP, Demmler GJ, Munoz FM.26.
Medically attended paediatric influenza during
the resurgence of the Victoria lineage of
influenza B virus. Int J Infect Dis 2007; 11: 40–7.
Ruf BR, Knuf M. The burden of seasonal and27.
pandemic influenza in infants and children.
Eur J Pediatr 2014; 173: 265–76.
Gasparini R, Durando P, Ansaldi F, et al.28.
Influenza and respiratory syncytial virus
in infants and children: relationship with
attendance at a paediatric emergency unit
and characteristics of the circulating strains.
Eur J Clin Microbiol Infect Dis 2007; 26: 619–28.
Rothman KJ. No adjustments are needed for29.
multiple comparisons. Epidemiology 1990; 1:
43–6.
48 |  hater 2







Gooskens J 1, Kuiken T 4, laas EJ 1, Harinck HI 2, 
Thijssen JP 1, Baelde HJ 3, Kroes AM 1
Journal of Clinical Virology 2007; 39: 136–40
1  Deartment of Medical Microbiology
Leiden University Medical enter, Leiden, the Netherlands
2  Deartment of Intensive are
Leiden University Medical enter, Leiden, the Netherlands
3  Deartment of Pathology 
Leiden University Medical enter, Leiden, the Netherlands
4  Deartment of Virology
Erasmus University Medical enter, Rotterdam, the Netherlands
Abstract
Influenza-associated encephalopathy is a clinically diverse syndrome and severe cases
are not well documented outside Japan. Clinical, pathological and molecular aspects are
described of two fatal cases presenting during 2004 and 2005 winter seasons in the
Netherlands. Results showed that severe influenza can resemble hemorrhagic shock and
encephalopathy syndrome, and proper testing for influenza virus should be considered
in similar cases. The failure to detect viral replication in non-pulmonary organs
including the brain would support the pathogenesis of this syndrome is based on proin-
flammatory cytokine responses.
Introduction
Neurological impairment during acute human influenza is defined as influenza-
associated encephalopathy (IAE). Patients with IAE have rarely been documented
in Europe and North America after the 1957 pandemic [2,  5,  9,  20] and recent clinical
presentations are variable [12,  26]. In contrast, cases have frequently been described
among Japanese children, characterized by rapidly progressive coma (often <24 h) and
high mortality rates (50–100 annually from 1995 to 2000) [19,  21]. Viral RNA detection
in cerebrospinal fluid has been reported [6], but is considered a rare finding [7,  20].
Neuroinvasion is therefore disputed as a cause of neurological symptoms, whereas
an indirect role for proinflammatory cytokines is suggested as a more likely
 explanation [15,  26]. Neuroinvasion of avian influenza virus (A/H5N1) has been
confirmed in animal models and is suggested for human cases [4]. Distinct clinical
forms of encephalopathy associated with acute human influenza include Reye’s
syndrome, encephalitis, acute necrotizing encephalopathy [19] and the hemorrhagic
shock and encephalopathy syndrome (HSE) [22]. We report two patients with IAE and
unusual symptoms of hemorrhage, multiple organ failure and shock, admitted to our
hospital during the 2003–2004 and 2004–2005 winter seasons. Pathological and
molecular studies were performed on tissue specimens following autopsy in one case.
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Case reports
Patient 1. A previously healthy 9-year-old girl was found somnolent in the morning
with evidence of recent haematemesis. She had a 3-day history of sore throat, cough
and 38.5 °C fever, with nausea, vomiting and fever exceeding 40 °C during the previous
night. There was no influenza vaccination or acetylsalicylic acid ingestion. During
medical transportation she developed coma and required intubation. On admission, the
Glasgow Coma Scale was 3 with signs of respiratory distress, endotracheal hemorrhage,
epistaxis and diarrhea. Physical examination revealed a temperature of 37.4 °C and
blood pressure of 100/40 mmHg. There was no nuchal rigidity, papilledema, patho-
logical reflexes, petechiae, rash or mucous membrane abnormalities. Laboratory exami-
nation revealed hypoxia (85% O2 during mechanical ventilation), combined respiratory
and metabolic acidosis (pH 7.18, lactate 2.6 mmol/l), low white blood cell count (WBC
3200 mm-3 , 59% lymphocytes), renal failure (creatinine 197 µmol/l, urea 9.5 mmol/l) and
elevated LDH (752 U/l) and CPK (1455 U/l). She developed anemia (haemoglobin 9.0 to
4.4 mmol/l), leucopenia (WBC 600 mm-3), thrombocytopenia (31×109 l-1), coagulopathy
(PTT 31.5 s, aPTT 88.6 s, fibrinogen 1.2 g/l and D-dimer >5000 µg/l), elevated liver
enzymes (ASAT 193 U/l, ALAT 39 U/l), glucose (11.8 mmol/l) and amylase (2045 U/l). Chest
radiograph showed bilateral infiltrate formation and computed tomography (CT) of the
brain appeared normal. Cerebrospinal fluid was not obtained due to coagulopathy.
Rapid influenza antigen testing (nasal wash), influenza serology (complement fixation),
and viral throat cultures were negative. PCR of throat and nasal wash specimens
was positive for influenza A virus and negative for influenza B virus, human respira -
tory syncytial virus, parainfluenza virus 1–4, human metapneumovirus, rhinovirus,
 Myco plasma sp. and Chlamydophila sp. [17,  23,  24]. Viral culture from nasal wash revealed
an influenza virus, characterized by duplicate haemagglutination inhibition tests as
influenza A/H3N2/Fujian/411/02-like virus according to standard methods [13,  16] using
turkey erythrocytes and four haemagglutinating units of virus. Multiple blood and
other bacterial cultures were negative. Her condition rapidly deteriorated despite broad-
spectrum antibiotic treatment, dexamethasone and drotrecogin-alfa. She died within 24
hours due to shock, multiple organ failure and disseminated intravascular coagulation
(DIC). No autopsy was performed. This case occurred in the midst of the community
influenza season in December 2003.
Patient 2. A 17-year-old male adolescent with a stable ventricular septal defect became
progressively somnolent following a 1-day history of flu-like symptoms, diarrhea and
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neck pain. There was no influenza vaccination or acetylsalicylic acid ingestion. During
admission, he progressed into coma (Glasgow Coma Scale 10 to 3) without respiratory
symptoms. Profuse hemorrhagic secretions were retrieved during intubation. Physical
examination revealed a temperature of 33.7 °C, blood pressure of 90/50 mmHg and
skin mottling. There was no nuchal rigidity, papilledema, pathological reflexes,
petechiae, rash or mucous membrane abnormalities. Laboratory results revealed 100%
oxygen saturation (breathing 5 l oxygen), severe lactic acidosis (pH 6.78, lactate 15.7
mmol/l), leukocytosis 31,200 mm-3, haemoglobin 9.5 mmol/l, progressive coagulopathy
(thrombocyte count 88×109 l-1, PTT 19.0 s, aPTT 98.6 s, fibrinogen 1.3 g/l), renal failure
(creatinine 288 µmol/l, urea 12.6 mmol/l), and elevated liver enzymes (ASAT 108 U/l,
ALAT 25 U/l), glucose (22.4 mmol/l), thyroid-stimulating hormone (14.630 mU/l), LDH
(1210 U/l) and CPK (1782 U/l). Toxicology screening was negative. Chest radiograph
and electrocardiography appeared normal. CT of the brain was normal, but revealed
sphenoid and maxillary sinusitis. Cerebrospinal fluid was not obtained due to coagu-
lopathy. Multiple blood and other bacterial cultures were negative. His condition
rapidly deteriorated despite broad-spectrum antibiotic treatment, dexamethasone and
drotrecogin-alfa. He died within 24 hours due to progressive multiple organ failure, DIC
and shock. Autopsy was performed following parental permission. PCR detected
influenza A virus [23] from fresh pulmonary and sinus tissue specimens, but not from
pleural and pericardial fluid obtained during autopsy. PCR was negative for other
 respiratory viruses. Influenza virus cultured from sinus tissue was antigenically
 characterized as influenza A/H3N2/Wyoming/003/03-like virus. This case occurred
in the midst of the community influenza season in February 2005.
Pathological and molecular analysis
Pathology. Autopsy (patient 2) and tissue preparation was performed according to
standard procedures, taking precautions to minimize RNA degradation (rapid tissue
preparation and fixation to minimize autolysis) and to prevent contamination (separate
autopsy of the brain; individual tissue processing in separate cassettes; solitary tissue
cutting by sterile microtome and disposable blades). Macroscopic findings included
edematous lungs with hemorrhagic pleural fluid. Microscopic examination did not
detect encephalitis, necrosis or other abnormalities in the pons, striatum, mesen-
cephalon, hippocampus, cerebellum or four ventricle biopsy specimens. Pulmonary
tissue revealed multifocal hemorrhage, bronchitis and early diffuse alveolar damage.
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The liver contained no fatty changes and other organs had no major abnormalities.
Streptococcus pneumoniae, Neisseria meningitidis, herpes simplex virus, varicella-zoster
virus and enterovirus  were excluded by PCR or polysaccharide antigen testing on post-
mortem cerebrospinal fluid. Fresh specimens were not available for further molecular
testing. 
Immunohistochemistry. Formalin-fixed paraffin-embedded (FFPE) tissue sections of
4 µm were deparaffinized, hydrated and treated with pronase for 10 min at 37 °C. The
monoclonal mouse-anti-Influenza A nucleoprotein (IgG2a, Hb65, ATCC) was diluted
in PBS/0.1% BSA and incubated with the section for 1 h at room temperature, and bound
antibody was detected with an alkaline phosphatase labeled (AP) goat-anti-mouse
IgG2a. AP was revealed with fast red chromogen substrate resulting in pink/red
 precipitate. Focal specific nuclear staining was mainly observed in pulmonary bronchial
epithelium cells and in very few cells in the alveoli (type undetermined), but not in
other organs (Table 1).
Molecular analysis of viral expression. RNA was extracted from alternate clinical
and negative control FFPE tissue sections. Ten 4 µm sections were deparaffinized
(xylene), rehydrated and digested overnight at 50 °C in 200 µl lysis buffer (500 µg/ml
proteinase K (Roche, Mannheim, Germany) in 20mM Tris (pH 7.4), 1mM EDTA (pH 8.0),
2% SDS). RNA was isolated (TRIzol reagent, Invitrogen, Carlsbad, CA, USA), precipitated
(2-propanol, 3 µl of 2 mg/ml glycogen), washed (500 µl of 75% ethanol), dried and re -
suspended (60 µl). Purity and quantity of extracted RNA was measured (NanoDrop
Technologies, Wilmington, USA). OD 260/280 ratios were ≥1.8 for most sections
indicating high purity [3] except for brain tissues with OD ratios <1.8. In addition, the
RNA concentration extracted from brain specimens was somewhat lower. Influenza
PCR was performed using previously published primers and probe with an equine
arteritis virus internal control [23,  17]. Influenza A RNA was detected in all organs
(Table 1). A molecular assay was developed for detection of influenza mRNA indicating
viral replication. The primers 851FLUA-M2s 5’-GAGYCTTCTAACCGAGGTC and 852FLUA-
M2as 5’-CAACAACAAGCGGGTCAC amplified an 83 bp spliced fragment of M2 mRNA
as confirmed by sequence analysis (Figure 1), and a 771 bp unspliced fragment of
M1 mRNA or viral RNA. The optimized assay was performed using the Qiagen
OneStep RT-PCR kit (Qiagen, Hilden, Germany) with 0.2mM dNTP’s, 3.5mM MgCl2,
30 pmol each primer and 10 µl extracted RNA. Cycling conditions were 30 min at 50 °C
(cDNA synthesis) and 45 cycles (95 °C, 30 s; 51 °C, 30 s; 30 s at 72 °C). PCR product was
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analyzed by gel electrophoresis. Spliced M2 mRNA was detected in pulmonary tissue,
but not in other organs (Table 1). The sensitivity of the PCR to detect influenza mRNA is
unknown and especially difficult to determine in fixed specimens. Spliced M2 mRNA
was consistently detected from fixed pulmonary tissue. In addition, spliced mRNA was
consistently detected down to a 1:3125 dilution in controls of influenza infected MRC-5
cells, with the knowledge that mRNA is a low abundant messenger.
Table 1.  Molecular and immunohistochemical detection of influenza A RNA, antigen and spliced
mRNA in paraffin-embedded tissue specimens.
t, cycle threshold; M2, matrix gene segment encoding influenza M2 rotein; EAV, equine arteritis virus.
a Fixed negative controls, araffin-embedded ulmonary (cynomolgus macaques) and tonsil (human) tissues.
b Fixed negative controls, isotye- and omission controls.
c Fixed influenza B control, ost-mortem araffin-embedded lung tissue from a atient with influenza B neumonia.
d Fixed influenza A antigen ositive control, araffin-embedded ulmonary tissue of an exerimentally infected cat
with influenza A (04-7992-2).
e mRNA ositive control, RNA extracted from MR-5 human lung cells infected by influenza A virus (field isolate).
f Influenza A RNA ositive control, RNA extracted from suernatant of LL-MK2 cells infected by influenza A virus
(field isolate).
g o-amlification with EAV sike as internal control revealed no evidence for inhibition.





















nontrol (fixed lung) a — — — 27.2 81 1.8
Heart + (36.9) — — — 28.0 83 1.8
nontrol (fixed lung) — — — 27.3 92 1.8
Liver + (37.5) — — — 27.6 289 1.8
nontrol (fixed lung) — — — 27.5 90 1.8
Kidney + (35.6) — — — 26.2 118 1.8
nontrol (fixed lung) — — — 27.1 74 1.8
Mesencehalon — — — — 27.2 8.9 1.6
nontrol (fixed lung) — — — 27.2 69 1.8
Pons + (37.6) — — — 26.6 18 1.7
nontrol (fixed lung) — — — 28.1 66 1.9
Lung + (24.8) — + + 30.1 545 1.8
nontrol (fixed tonsil) a — — — — 26.8 114 1.8
nontrol (isotye/omission) b —
Influenza B control (fixed) c — + (33.3) — 26.6 51 1.7
Influenza A control (fixed) d +
Influenza A control (culture) e +
Influenza A control (culture) f + (33.1) —
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Figure 1. Sequence analysis of the 83 bp M2 mRNA PCR product amplified from RNA extracted
from MRC-5 human lung cells infected with influenza A virus (field isolate). 
M2 mRNA was confirmed by detection of sliced influenza matrix gene RNA. The slice site (arrow)
corresonds to osition 51-A740 (A/New York/206/2005; Gen-Bank Accession number Y006132).
Discussion
Two patients with IAE are described, who had rapidly progressive coma during acute
influenza infection. The clinical findings and outcome differed substantially from
recent Dutch cases with IAE [18,  26]. Although fatal cases of IAE occurred in Japan, fatal
cases of IAE have not been documented in the Netherlands after the 1957 pandemic,
when 68 patients (mainly children) died during a 3-month period [25]. 
Clinical similarities to recent Japanese cases include sudden high fever, vomiting
or diarrhea, early onset and rapid progression of coma, multiple organ failure and
 haemodynamic shock [15]. Comparable laboratory results include thrombocytopenia,
prolonged coagulation tests and elevated levels of transaminases, LDH and CPK.
Differences in our cases include a higher age (most Japanese cases <5 years old), lack of
documented convulsions and absence of convincing brain CT abnormalities. Acute
necrotizing encephalopathy was excluded in both patients by brain CT [14]. In addition,
influenza A RNA was isolated from brain tissue of patient 2. Influenza RNA has not been
reported in brain tissue or cerebrospinal fluid of patients with acute necrotizing
encephalopathy. Reye’s syndrome is considered unlikely as the patients received no
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acetylsalicylic acid, were hyperglycemic, and had only mildly elevated liver enzyme
levels. The absence of hepatic fatty changes and neural inflammatory cell infiltration
also excludes Reye’s syndrome and encephalitis as the cause of coma in patient 2.
Importantly, clinical symptoms of both patients strongly resembled HSE using the
described criteria [1,  11]. Criteria for HSE for patient 1 were not met due to unavailability of
cerebrospinal fluid and the solitary elevated hepatocellular enzyme levels without clear
evidence for hepatic dysfunction. Criteria for HSE for patient 2 were not met because of
the modest reduction of haemoglobin levels and the solitary elevated hepatocellular
enzyme levels without clear evidence for -hepatic dysfunction. Hepatocellular enzyme
profiles reflected rhabdomyolysis rather than hepatic dysfunction in both patients. HSE is
a severe syndrome with unknown aetiology [10], and associations with acute influenza are
confined to Japan. Similar to Japanese findings [22], we detected influenza RNA in multiple
organs inclu ding the brain taken at autopsy from patient 2. In contrast to Japanese
findings, we found no evidence of viral replication in nonpulmonary tissues containing
influenza RNA, which could be explained by residual deposition of disseminated influenza
RNA from replication elsewhere (lungs) or by the presence of undetectable low-level
influenza antigen and mRNA in these non-pulmonary tissues. This would further
implicate proinflammatory cytokine responses in the pathogenesis of this syndrome. The
rapid clinical deterioration in both patients suggests that antiviral therapy will have little
chance of success in hospitalized patients presenting with advanced stage of IAE and HSE-
like symptoms. Antiviral intervention during early stages of influenza-like illness might
have altered the outcome of the patients described. Additional supportive and immu -
nomodulating therapeutic measures during hospital admission have been sug gested [8].
The protective role of influenza vaccination during early stages of child hood, to prevent
rare IAE and HSE-like complications during later stages of childhood or adolescence,
remains to be determined. 
In conclusion, severe influenza can resemble HSE syndrome, emphasizing the need for
appropriate diagnostic efforts to demonstrate influenza virus infections in similar
cases. Molecular detection of influenza mRNA can be used to detect local influenza
replication in archival and clinical specimens.
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Abstract
Background: Nursing home influenza outbreaks occur in spite of established vacci-
nation programs, and require rapid and sensitive laboratory confirmation for timely
intervention.
Objectives: To evaluate diagnostic approaches for rapid confirmation of nursing home
influenza outbreaks.
Study design: Influenza virus real-time PCR and Directigen Flu A+B enzyme immu -
noassay were performed on nasopharyngeal swabs, nasopharyngeal washes and throat
swabs collected from residents with clinical suspicion of influenza during seven
probable nursing home outbreaks in 2004–2005 and 2005–2006. The efficacy of
specimen sampling and transport management by Public Health Service outbreak team
was evaluated.
Results: PCR detected influenza RNA in 80% (68/85) of specimens from 81% (38/47)
residents, confirming six suspected outbreaks. Immunoassay sensitivity was highest on
nasopharyngeal swabs (38%; 11/29) with a positive predictive value of 100% compared to
PCR. Nasopharyngeal swabs were equally sensitive to nasopharyngeal washes by PCR.
Nasopharyngeal wash sampling appeared unpractical due to common underlying
disability of residents. Outbreak team support was associated with a shorter time to PCR
diagnosis compared to outbreaks with no logistical support (mean, 28.2 h vs. 84 h;
P = 0.05).
Conclusions: Influenza real-time PCR on nasopharyngeal swabs, obtained by Public
Health Service outbreak teams, enabled rapid and sensitive confirmation of nursing
home influenza outbreaks.
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Introduction
Influenza outbreaks in nursing homes are associated with increased morbidity, hospi-
talization and mortality among residents [8]. Influenza vaccination effectively reduces
the incidence of influenza-like illness (ILI) and associated complications [17], but
outbreaks continue to occur with a high burden of disease [6,  12,  16,  19,  26]. The low
protection rate among vaccinated elderly is related to the aging immune system, under-
lying disease and in some cases immunosuppressive medication. Influenza outbreaks
are further determined by local vaccination rates of residents and staff [12], vaccine
match to circulating strains and waning vaccine-induced immunity due to late seasonal
occurrence. New nursing home influenza guidelines therefore recommend additional
hygiene and cohorting measures during suspect outbreaks [4,  26], extending to re-
offering of influenza vaccination and oseltamivir ‘postexposure prophylaxis’ during
confirmed outbreaks [4,  7,  21]. These measures invariably require rapid and sensitive
diagnostic confirmation, a paradigm that is challenged by the use of slow and insen-
sitive conventional laboratory techniques and lack of established logistical support
regarding specimen transport and communication strategy [14]. Nursing home influenza
outbreak-control would likely benefit from the support of Public Health Services (PHS)
to raise influenza awareness, facilitate diagnostic efforts and implement control
measures [5,  11]. For diagnostic efforts, nasopharyngeal washes are considered most
sensitive [18], however this has not yet been specifically evaluated among elderly. Recent
studies demonstrate the importance of detection of other respiratory viruses associated
with outbreaks [1,  2,  8,  13]. The present study evaluated rapid influenza immunoassay and
PCR detection on nursing homes specimens, and the efficacy of PHS outbreak team
support.
Methods
Public Health Service outbreak teams. PHS and nursing home health care workers
from the region ‘Hollands Midden’ in the Netherlands received training in early recog-
nition of clinical influenza, respiratory tract sampling techniques and application of new
outbreak-control guidelines. Regional nursing homes were invited by mail to report
probable influenza outbreaks during the 2004–2005 and 2005–2006 winter seasons to
the PHS department. PHS outbreak teams (physicians and nurses) were responsible for
specimen and data collection, transport, advice in outbreak manage ment, and commu-
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nication with laboratory staff. A microbiological laboratory performed influenza
immunoassay daily during and outside office hours and daily PCR during office hours.
Outbreak procedures. In seven nursing homes with a probable outbreak, clinical
specimens were simultaneously obtained from residents with clinical suspicion for
influenza. A probable influenza outbreak was defined as two or more residents from
the same ward developing four of the following symptoms within 48 h of each other:
headache, myalgia, throat pain, fever of sudden onset, cold chills, dry cough and
malaise. Nursing homes requested PHS support in five of the seven probable outbreaks.
The two remaining outbreaks were sampled and managed by local nursing home
health care workers. Temperature and respiratory symptoms were recorded and data
obtained by questionnaire included demographics (age, sex), influenza vaccination
status, antibiotic use, acute onset (≤48 h) and symptom duration. Clinical data from
confirmed cases were compared to ILI criteria defined as a fever (≥38 ˚C), plus a new
onset or acute worsening of one or more respiratory symptoms. Nasopharyngeal wash
(5 ml PBS each nostril) volume recovery was variable (2–8 ml). Nasopharyngeal swabs
(flexible wire, rayon) and throat swabs (woodstick, cotton) were stored in 3ml VTM.
Directigen Flu A+B enzyme immunoassay (Becton Dickinson, MD, USA) was performed
following the manufacturer’s instructions. Multiplex real-time PCR detection of
influenza and other respiratory viruses were performed as described previously [20,  25].
PCR cycle threshold (Ct) levels were determined as a surrogate quantitative marker of
viral genome equi valents. Viral culture was performed for antigenic typing of circu-
lating viruses from selected specimens. 
Influenza typing. Antigenic typing was performed on cultured influenza strains
by duplicate haemagglutination inhibition (HI) testing as described previously [9].
For outbreaks with antigenic heterogeneous strains, the two antigenic most deviant
viruses were compared by sequence analysis of 1015 bp of the hemagglutinin HA1 gene
fragment (including globular antigenic domains) using primers 983FLUH3s 5’-
ATCATTGCTTTGAGCTACATT, 984FLUH3as 5’-AACGTGACTATGCCAAAC, 985FLUH3as
5’-CCCAAATGTACAATTTGTCAA and 986FLUH3as 5’-CTTCCCAACCATTTTCTATG.
Statistical analysis. SPSS software version 11.0.1 (SPSS, Chicago, Illinois, USA) was used
to calculate differences in categorical measurements (Pearson chi-square) and continuous
variables (unpaired and paired Student’s t-test). Comparative evaluation of diagnostic
delay (hours) with and without outbreak team support was performed using Mann–
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Whitney U-test. Linear regression analysis was used to correlate PCR results from
nasopharyngeal swabs to paired nasopharyngeal washes and throat swabs.
Results
Laboratory detection of influenza and other respiratory viruses. PCR detected
influenza RNA in 68/85 (80%) specimens among 38/47 (81%) residents (Table 1A).
PCR-based typing revealed 36 (95%) residents with influenza A, 2 (5%) residents with
influenza B and no residents with mixed influenza infections. Sensitivity of viral culture
(54%; 14/26) and immunoassay (22%; 14/65) were low compared to PCR. Some outbreaks
were missed by immunoassay on individual specimens (Table 1A). The immunoassay
sensitivity was highest on nasopharyngeal swabs (38%; 11/29) with 100% positive
predictive value compared to PCR. Rhinovirus (n = 2), human metapneumovirus (n = 2)
and parainfluenza virus 4 (n = 1) were only detected from patients with influenza and
not associated with outbreaks.
Characteristics of residents with confirmed influenza. We enrolled 47 residents with
38 confirmed cases of influenza (26 female, median age 85 years) (Table 2). Main symptoms
were fever (83%), cough (63%) and malaise (60%). Absence of fever among symptomatic
elderly with confirmed influenza (n = 6) was the most important cause of a low sensitivity
using ILI criteria (69%). Confirmed cases were frequently vaccinated (82%) and often
treated with antibiotics during infection (57%). Physical (aging, underlying or current
disease) or mental (dementia) disability frequently limited the collection of clinical data
(Table 2) and nasopharyngeal wash sampling (Table 1A) among elderly residents.
Influenza outbreaks, diagnostic intervals and typing results. Influenza was
confirmed in 6 of 7 probable outbreaks (5 by influenza A/H3N2; 1 by both influenza A
and B strains not further typed), occurring during normal influenza seasons (Table 1B).
Time from sampling to report of immunoassay results with outbreak team support was
10.8 h (mean, range 4–19 h). PCR diagnostic intervals with the use of outbreak team
support (mean 28.2 h, range 20–42 h) were significantly shorter than without support
(mean 84 h, range 72–96 h) (Mann–Whitney U-test, P = 0.05). Logistical problems
included delays in specimen transport and handling, laboratory testing and communi-
cation of laboratory results outside normal office hours. Cultured influenza viruses
were typed A/H3N2 by HI testing (Table 1B). Viruses from outbreak A, and occasionally
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outbreak B and D were closely related to the vaccine strains. Influenza A/H3N2 viruses
from outbreaks B and D revealed intrinsic HI titer variability (range 160–960), suggesting
co-circulation of multiple H3N2 strains. Sequence analysis of two most antigenic deviant
viruses for each outbreak (Outbreak B 05014614, 05014606; Outbreak D 06017519,
06017544), demonstrated identical HA1 gene sequences within each outbreak. Strains
from both outbreaks differed in HA1 gene sequence indicating seasonal drift.
Table 1A. Molecular and antigen detection of influenza virus and other respiratory virus.
Table 1B. Influenza outbreak management and typing results.
Nursing home Influenza PCR+ Immunoassay+/PCR+ Multiplex PCR+
Residents Specimens NPW NPS TS Residents with otherrespiratory viruses
2005
A 8/9 13/14 1/5 4/8 NA 0
B 8/10 8/10 NA NA 1/8 0
 8/8 14/14 0/6 a 3/8 NA 1 hMPV
2006
D 7/8 19/22 0/5 a 2/7 0/7 a 2 hRV
E 2/4 2/4 NA 0/2 a NA 1 PIV4
F 0/2 0/6 NA NA NA 0
G 5/6 12/15 1/3 2/4 0/2 a 1 MPV
Total 38/47 68/85 2/19 11/29 1/17
NA, not alicable; NPW, nasoharyngeal wash; NPS, nasoharyngeal swab; TS, throat swab; 
hMPV, human metaneumovirus; hRV, human rhinovirus; PIV4, arainfluenza virus 4. 
a  Influenza outbreak not detected by raid antigen test on current secimens.
Nursing home
residents 
Outbreak date Outbreak management Influenza typing








A (9) February 2005 + 22 5 A A/H3N2 ≥960
B (10) February 2005 − 96 a NA A A/H3N2 r 160–960 b
 (8) March 2005 + 42 19 A A/H3N2 NA
2006
D (8) March 2006 + 20 15 A A/H3N2 r 160–960 b
E (4) March 2006 − 72 a NA A A/H3N2 160
F (2) March 2006 + 29 NA NA NA NA
G (6) March 2006 + 28 4 A+B ulture− ulture—
NA, not alicable; HI, haemagglutination inhibition.
a  PR diagnostic interval without outbreak team suort.
b  Post-infection ferret antisera to H3N2 strains A/Wyoming/003/03 (home B) and A/alifornia/007/04 (home D).
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Table 2.   Demographic and clinical characteristics of residents with confirmed influenza by PCR.
Evaluation of influenza PCR cycle threshold values. Immunoassay positive
nasopharyngeal specimens had significantly lower PCR Ct values (mean 22.9, range
17.6–28.7) compared to immunoassay negative specimens (mean 31.5, range 18.9–43.3;
P <0.0001) (Figure 1). Total nasopharyngeal swabs seemed more sensitive than nasopha-
ryngeal washes by immunoassay (11/29 vs. 2/19) and PCR (mean Ct values 28.1 vs. 30.6;
P = 0.18). However, paired nasopharyngeal swabs and nasopharyngeal washes (n = 18)
revealed more comparable immunoassay results (4/18 vs. 2/18) and equally sensitive
and correlated PCR results (r2 = 0.55, P <0.0001; mean Ct difference −0.1, P = 0.94)
(Figure 2A). Nasopharyngeal swabs were significantly more sensitive than paired throat
swabs by immunoassay test (4/11 vs. 0/11) and PCR (−4.7, P = 0.005) with significant
correlation (r2 = 0.61, P = 0.005) (Figure 2B).
Characteristics Influenza PCR+
Patients
Total 38/47        (81%)
Female 26/38        (68%)
Median age (range years) 85             (61–97)
Influenza vaccination 23/28        (82%)
Antibiotic theray 12/21        (57%)
Symptoms
Fever (≥38 ˚) 29/35       (83%)
ough 22/35       (63%)
Malaise 12/20       (60%)
URTI (throat ain/runny nose) 16/29       (55%)
Muscle ain 13/28       (46%)
Acute onset (≤48 h) 15/35       (43%)
Headache 6/20         (30%)
Vomiting 6/27         (22%)
Diarrhea 4/27         (15%)
ILI criteria+ 24/35       (69%)
Prolonged duration (≥7 days) 9/12         (75%)
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Figure 1.   PCR Ct values compared to immunoassay results in nasopharyngeal specimens.
Figure 2.   Correlation of PCR Ct values from paired nasopharyngeal washes and swabs (A) and from
paired throat and nasopharyngeal swabs (B).
Discussion
Early intervention during nursing home influenza outbreak leads to improved control
[3,  7,  21], but depends on rapid and sensitive laboratory confirmation that proves difficult
to implement [5,  14]. This study evaluates diagnostic approaches for rapid confirmation
of nursing home influenza outbreaks, with support of the PHS department. 
Evaluation of the adequacy of sampling revealed important practical and diagnostic
insights. Nasopharyngeal washes are considered most sensitive specimens for detection
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of respiratory viruses in adults [18], however wash sampling proved to be unpractical
among frail elderly with common mental or physical disability. Nasopharyngeal swabs
revealed a high concordance to paired nasopharyngeal wash specimens by PCR
(Figure 2A), not significantly affected by VTM dilution. Nasopharyngeal swab PCR Ct
values were continuously 4.7 cycles lower than in paired throat swabs indicating a
10-100-fold higher sensitivity. Outbreak team support was associated with shorter PCR
diagnostic intervals (mean, 28.2 h vs. 84 h; P = 0.05), indicating that outbreak team
measures directly can accelerate nursing home influenza outbreak diagnosis. We
conclude that PCR on nasopharyngeal swabs obtained by PHS outbreak teams provide
most practical and sensitive confirmation of nursing home influenza outbreaks. 
PCR sensitivity was clearly superior to culture and immunoassay. Compared to PCR,
immunoassay sensitivity on total specimens was low (22%; 14/65) similar to other
studies [10,  23], but higher on nasopharyngeal swabs (38%). Immunoassays are noto -
 riously unreliable to detect outbreaks, illustrated in this study on individual specimens
(Table 1A). A similar performance could be expected from other immunoassay tests
[15,  22]. Alternative sampling techniques could be studied to increase immunoassay sensi-
tivity, including the use of flocked swabs. Immunoassays remain attractive for their
convenience, speed and high positive predictive value (100%), however negative results
should always be confirmed by more sensitive tests. 
All influenza outbreaks presented in the midst of influenza seasons. Outbreaks among
residents with clinical suspicion for influenza were not associated to other respiratory
viruses capable of causing outbreaks [1,  2,  8,  13]. Influenza outbreaks are mainly
associated with low vaccination coverage among residents or poor vaccine match.
Relevant findings were that residents with confirmed influenza were often vaccinated
(82%) and that all cultured influenza viruses matched the vaccine strains. These results
are in agreement to recent 2004–2005 cross-sectional surveys in the Netherlands [26]
describing nursing homes with high vaccine coverage frequently experiencing clinical
(49%) and laboratory confirmed (29%) influenza outbreaks. Similarly, Canadian surveys
demonstrated influenza outbreaks in more than one third of highly immunized nursing
homes [24]. High attack rates (≥50%) and case-fatality rates are reported during influenza
outbreaks in nursing homes with high vaccine coverage [6,  14], underlining the impor-
tance of rapid diagnostics and outbreak prevention and control. In this study, influenza
viruses isolated from three outbreaks (A, B and D) were antigenically highly related to
the vaccine strains. This could be explained by waning immunity since the outbreaks
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presented 5–6 months after vaccination, or insufficient vaccine protective immunity
against the circulating strains as documented previously for 2004–2005 influenza
outbreaks [16]. Influenza viruses with variable HI titers (range 160–960) isolated during
Outbreak B and D had identical HA1 sequences. Alternative explanations for antigenic
variability of these strains are posttranslational modification of the HA1, mutations in
other antigenic domains, difference in avidity due to conformational changes or
intrinsic haemagglutination inhibition test variability. The clinical significance of
these findings remains to be determined. 
In conclusion, this study offers further insight to the feasibility of practical and rapid
confirmation of nursing home influenza outbreaks by PCR with support of trained PHS
outbreak teams. Data on logistical aspects of rapid confirmation of outbreaks are much
awaited with the increasing concerns about epidemiological aspects of influenza.
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Abstract
The factors that cause prolonged human influenza virus respiratory tract infection and
determine its clinical impact and the development of drug-resistant viruses are unclear.
During a 3-year period, symptomatic influenza virus excretion for ≥2 weeks was
observed among 8 immunocompromised patients and found to be associated with
lymphocytopenia at onset (8 of 8 patients) more often than with granulocytopenia (2 of
8 patients) or monocytopenia (2 of 8 patients). Six (75%) of 8 patients developed
influenza lower respiratory tract infection (10 episodes), and receipt of oseltamivir
treatment was significantly associated with clinical improvement (8 of 8 episodes vs. 0
of 2 untreated episodes; P = .02). Complete viral clearance was strongly correlated with
lymphocyte reconstitution (P = .04) but was never observed during the first 2 weeks after
oseltamivir treatment. Neuraminidase inhibitor-resistant influenza viruses emerged in
2 (67%) of 3 patients eligible for resistance analysis. In conclusion, prolonged influenza
virus infection was associated with lymphocytopenia, influenza lower respiratory tract
infection, and frequent development of drug resistance during antiviral therapy. Clinical
improvement in influenza lower respiratory tract infection is observed during
oseltamivir treatment, but complete viral clearance is dependent on lymphocyte recon-
stitution, irrespective of receipt of antiviral medication.
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Introduction
Human influenza viruses cause frequent morbidity and mortality, particularly in high-
risk populations [1]. Antiviral drugs are important for treatment of infection and
control of transmission during seasonal and pandemic influenza [2]. The recent and
unexplained widespread emergence of circulating human influenza viruses with
reduced sensitivity to adamantanes and neuraminidase (NA) inhibitors (NAIs) is
therefore of major concern [2–5]. The potential modes by which NAI-resistant influenza
viruses emerge merit further analysis. Particularly among children and immunocom-
promised hosts, prolonged viral excretion is associated with a higher incidence of drug
resistance during antiviral therapy [6–13]. The frequency with which such prolonged
influenza viral excretion occurs, the clinical consequences of this condition, the
 development of antiviral resistance, and its correlation with impaired cell-mediated
immunity are unclear, however [1,  14]. During a 3-year period, these questions were
addressed through careful analysis of findings in 8 patients who presented with
prolonged influenza virus respiratory tract infection.
Methods
Patients and specimens. The study included patients with prolonged influenza virus
respiratory tract infection (defined below) observed at Leiden University Medical Center
from March 2005 through April 2008. Respiratory specimens were obtained during
episodes of symptomatic respiratory tract disease. Routine follow-up sampling was not
performed during asymptomatic episodes that occurred in patients with established
prolonged influenza virus infection, except for patient 1 and on single occasions for
patients 3–6 to document complete viral clearance. Influenza virus type A or B RNA was
detected in respiratory specimens by reverse-transcriptase polymerase chain reaction
(PCR) [15]. Medical records were reviewed for underlying immunodeficiency and clinical
characteristics during presentation, follow-up, and outcome, including upper or lower
respiratory tract infection symptoms, intubation, antiviral therapy, viral clearance,
leukocyte counts, hematopoietic stem cell transplantation (HSCT), and survival.
Minimum cell count percentages for granulocytes, monocytes, and lymphocytes deter-
mined within 1 week before or after initial detection of viral RNA (i.e., onset) were corre-
lated with percentages determined within 2 weeks after final influenza virus RNA
detection or within 1 week before fatal influenza pneumonia. 
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Definitions. Prolonged influenza virus respiratory tract infection was defined as PCR-
positive status combined with symptomatic respiratory tract disease for ≥2 weeks after
primary laboratory confirmation of influenza virus infection. This definition is based on
documented maximum durations of excretion and approximate median duration of
symptoms among immunocompetent children (duration of excretion, <14 days; duration
of symptoms, 7.1 days) [16,  17] and adults (duration of excretion, 5.5 days; duration of
symptoms, 6 days) [18,  19] and mean durations of excretion among immunocompromised
autologous HSCT recipients (6.7 days) and allogeneic HSCT recipients (11.1 days) [20].
Influenza lower respiratory tract infection was diagnosed clinically (as dyspnea) and by
PCR, and fatal influenza pneumonia was diagnosed by histology and PCR of pulmonary
tissue specimens. Minimum reference cell counts for granulocytes (1800 cells/mm3),
monocytes (135 cells/mm3), and lymphocytes (900 cells/mm3) were used for adults, and
pediatric values were age dependent. These thresholds were used to determine granulo-
cytopenia, monocytopenia, and lymphocytopenia. Precursor virus was defined as
influenza virus detected in a patient before antiviral therapy was started. Seasonal viruses
were defined as community-acquired influenza viruses collected from patients with
influenza-like illness or acute respiratory infection who had consulted a general practi-
tioner involved in the sentinel surveillance system in The Netherlands. Baseline NAI
susceptibility for seasonal viruses was defined as the IC50 value (i.e., the mean concen-
tration of NAI needed to inhibit the NA enzyme activity by 50%), after removal of outlier
IC50 values. NAI drug resistance was defined as a viral IC50 value ≥8-fold higher than
that of the corresponding sensitive precursor virus [21] and detection of specific NA gene
mutations known to confer NAI drug resistance. In the absence of a precursor virus
isolate, the IC50 of a presumed drug-resistant isolate was compared with baseline NAI
susceptibility to calculate the n-fold change in drug susceptibility. 
Influenza virus characterization and drug susceptibility testing. Influenza virus-
eswere cultured in Madin-Darby canine kidney cells from specimens stored at -80°C.
Antigens were characterized by hemagglutination inhibition testing, as described
elsewhere [22]. Phenotypic susceptibility (IC50) for oseltamivir carboxylate (GS4071;
Roche Diagnostics) and zanamivir (GG167; GlaxoSmithKline) was determined as
described elsewhere [23]. Emergence of NAI-resistant viruses was confirmed by pheno-
typic and sequence analysis of precursor viruses. Influenza virus RNA was extracted
from culture supernatant or clinical specimens using the QIAamp Viral RNA kit
(Qiagen). Specific primers (available on request) were used for transcription (Thermo -
Script reverse transcriptase; Invitrogen) and cDNA amplification (Phusion High-Fidelity
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Taq polymerase; Finnzymes) of influenza NA, hemagglutinin (HA) and matrix 2 (M2)
genes. DNA sequences were analyzed using Bionumerics software (version 5.1; Applied
Maths). 
Data analysis. Patients treated with oseltamivir and untreated patients were compared
with respect to clinical recovery from lower respiratory tract infection, by use of
Pearson’s chi-square tests and 2-sided Fisher’s exact tests (SPSS software, version 14.0.2;
SPSS). The percentages of the granulocyte, monocyte, and lymphocyte minimum cell
counts at onset were compared with the percentages of these counts during viral
clearance, by use of the Wilcoxon matched-pairs signed rank test.
Results
Patients with prolonged influenza virus respiratory tract infection. Eight immuno-
compromised patients (median age, 52 years [range, 0–66 years]) were identified who
had prolonged influenza virus excretion (median duration of excretion, 29.5 days [range,
14–275 days]) and symptomatic respiratory tract disease (Table 1). These patients’ under-
lying diseases included hematological malignancy (n = 7) and severe combined immuno -
deficiency (n = 1). The duration of symptoms observed by healthcare workers before the
first detection of influenza virus was 2 days for patient 5 (coryza and fever), 2 days for
patient 8 (dyspnea), 4 days for patients 2 and 3 (dyspnea and fever), 14 days for patient
6 (cough), and 20 days for patient 7 (cough). For patient 1, the duration of symptoms
(cough) was 6 weeks before the first viral isolation, according to the history provided by
a parent. Symptom duration could not reliably be determined for patient 4, who had
chronic underlying pulmonary disease. Lymphocytopenia was more common at the
onset of prolonged influenza virus infection (8 of 8 patients) than were granulocy-
topenia (2 of 8 patients) or monocytopenia (2 of 8 patients). 
Influenza virus characterization. Viruses cultured from 4 patients were characterized
as influenza A/Wyoming/003/03 (H3N2)–like (patient 1), A/California /007/04 (H3N2)–
like (patient 2), A/Wisconsin/67/05 (H3N2)–like (patient 5) matching corresponding
vaccine strains, and A/Solomon Islands/03/06 (H1N1)–like with a poor vaccine match
(patient 8) (i.e., ~16-fold difference by duplicate hemagglutination inhibition titers).
The remaining 4 influenza viruses A (H3N2) (patient 3), A (H1N1) (patient 6), and B
(patients 4 and 7) could not be cultured or remained uncharacterized.
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Table 1.   Patients with prolonged influenza virus excretion and sequential susceptibility results.























































































































































































































































































































































































































































































































































































Table 1. (continued) Patients with prolonged influenza virus excretion and sequential susceptibility results.




























































































































































































































































































































































































































































































































































































































































































































































































































































Detection of antiviral-resistant viruses. Five of 8 patients were treated with
oseltamivir (Figure 1). Two of the 5 (patients 4 and 8) were excluded from resistance
analysis because of low viral levels and no viral growth or because of NAI-resistant
precursor influenza virus. Among the 3 patients for whom resistance analysis was
performed (patients 1–3), NAI-resistant viruses emerged in patients 1 and 2. In patient 1,
an influenza A (H3N2) NA gene R292K escape mutant emerged during therapy, with a
>7000-fold increase in resistance to oseltamivir and a >20-fold increase in resistance to
zanamivir, compared with precursor virus (Table 1). This virus reverted to an NA gene
E119V mutant virus that had ~100-fold reduced susceptibility to oseltamivir compared
with precursor virus but was sensitive to zanamivir (Table 1). Continuous E119V virus
excretion was confirmed for 6 weeks during oseltamivir therapy and for >4 months after
cessation of antiviral therapy. Sequence analysis during follow-up revealed transient HA
gene T/A135T/A, A138S, D188D/N, and N/K189N/K substitutions at or near the receptor
binding site compared with precursor virus. In patient 2, a mixed population of influenza
A (H3N2) NA gene R292K (10%) and NA gene E119V (90%) escape mutants with HA gene
A138S substitution at the receptor binding site emerged during therapy (Table 1). Because
precursor virus isolation in cell culture was unsuccessful, possibly owing to low viral load,
it was not possible to generate precursor IC50 values. Nevertheless, HA and NA sequences
derived from the precursor clinical specimen were free of known resistance markers and
were very similar to those of seasonal A (H3N2) viruses. Therefore, the IC50 of the
antiviral-resistant A (H3N2) virus isolate that emerged could validly be compared with its
baseline NAI susceptibility and was ~300-fold for oseltamivir and ~6-fold for zanamivir.
The mixed population of NAI-resistant viruses subsequently reverted to sensitive wild-
type virus 3 weeks after discontinuation of oseltamivir. Influenza A M2 gene mutations
conferring adamantane resistance were detected in samples from 3 of 6 patients (patients
1–3). The influenza A (H3N2) M2 gene S31N mutations observed in samples from patients
2 and 3 were pre-existent and genetically stable, in contrast to the newly acquired A30S
mutation that subsequently reverted to adamantane-sensitive virus in patient 1. 
Clinical outcome and viral clearance. Six (75%) of 8 patients had 10 episodes of
influenza lower respiratory tract infection (Figure 1), and 4 patients required mecha -
nical ventilation. Oseltamivir treatment was associated with clinical improve ment of
lower respiratory tract infection (8 of 8 episodes; patients 1–4 and patient 8), compared
with untreated episodes in patients who died of influenza pneumonia (improvement in
0 of 2 episodes; patients 7 and 8) (P = .02, by Fisher’s exact test). Influenza lower respi-
ratory tract infection reappeared in 4 patients after antiviral therapy and clinical
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improvement (Figure 1). Renewed clinical deterioration was likely caused by the same
influenza A (H3N2) virus in each of 3 patients, because the NA gene sequences were
identical (≤0.1% mutation frequency) to those of the precursor virus. NA sequences
differed significantly among the 3 patients (>0.5% mutation frequency). Confirmed viral
clearance in 5 patients correlated with lymphocyte reconstitution (P = .04) (Figure 2) and
was attributed to successful HSCT (patient 1 at day 247 and patient 5 at day 22) or to
spontaneous lymphocyte reconstitution (patients 3, 4, and 6). In contrast, decreasing
lymphocyte counts were observed in 2 patients with fatal influenza pneumonia
(Figure 2). Viral clearance was never observed during the first 2 weeks after 8 courses of
oseltamivir administered to 5 patients (5 regular courses of 5–6 days; 3 prolonged
courses of 13–37 days) (Figure 1) or after unsuccessful HSCT (day 110, patient 1). Three
patients never received oseltamivir treatment (Figure 1); 1 died of unrecognized fatal
influenza pneumonia (patient 7), and 2 rapidly cleared the virus after lymphocyte recon-
stitution that followed successful HSCT (patient 5) or spontaneous lymphocyte reconsti-
tution that followed “mild” lymphocytopenia (i.e., 55% of reference minimum cell count)
at onset (patient 6).
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Figure 1.   Timeline for patients with prolonged excretion of influenza virus. 
Patient numbers correlate with numbers deicted in Table 1. Day 0 correlates with the day influenza virus
was initially detected by culture or PR. Data on antiviral suscetibility or resistance  were lacking for many
time oints when no viral isolate or RNA nucleotide sequence could be obtained because of low viral
levels and no viral growth. LRTI, lower resiratory tract infection; URTI, uer resiratory tract infection.
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Figure 2.   Cellular immune response (cell counts) during prolonged influenza excretion among
survivors (2A) and patients with fatal influenza pneumonia (2B). 
ell count during influenza onset was obtained ≤1 week before or after first ositive olymerase chain
reaction (PR) result for influenza; cell count during confirmed viral clearance or resumed influenza was
obtained ≤2 weeks after final ositive PR result; cell count during fatal influenza neumonia was obtained
≤1 week before fatal influenza neumonia. #Wilcoxon matched airs signed rank test revealed significant
lymhocyte reconstitution during confirmed viral clearance. NS, not significant.
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Discussion
The occurrence and clinical manifestations of prolonged influenza virus respiratory
tract infection and the associated risk of developing antiviral resistance are poorly
documented. This study included 8 immunocompromised patients who had sympto-
matic prolonged viral excretion for ≥2 weeks, with development of influenza lower
respiratory tract infection in 6 patients (10 episodes) and frequent detection of drug
resistance after therapy.
The occurrence of prolonged influenza virus infection among 8 patients during a 3-year
period in a hospital setting appeared to be more common than would have been
expected from the few cases documented in the literature [8–12]. All 8 patients in the
current study who had prolonged influenza virus infection were immunocompromised
with lymphocytopenia, but a few presented with either granulocytopenia (2 of 8
patients) or monocytopenia (2 of 8 patients). This suggests that unimpaired cell-
mediated immunity is important for the timely elimination of influenza viruses, a result
that agrees with earlier observations [14]. In this study, complete viral clearance was
associated with lymphocyte reconstitution (P = .04) (Figure 2) and was never observed
within the first 2 weeks after oseltamivir therapy (Figure 1). This provides new evidence
that complete influenza virus clearance depends on lymphocyte reconstitution,
irrespective of receipt of oseltamivir therapy. Variable outcomes among patients who
never received antiviral therapy indicate that the level and duration of lymphocytopenia
could determine later outcome during prolonged influenza virus infection.
NAI-resistant influenza viruses emerged in 2 (67%) of 3 patients eligible for resistance
analysis. This rate is much higher than incidences of oseltamivir resistance reported for
immunocompetent adults or adolescents (0.33%–2%) and pediatric patients (4%–18%)
during clinical trials [6,  7,  13]. Emergence of NAI-resistant influenza viruses was
confirmed in patients 1 and 2. In patient 1, an influenza A (H3N2) virus with NA gene
R292K substitution, which conferred high-level oselta mivir resistance (>7000-fold
increase, compared with precursor virus) and zanamivir resistance (>20-fold increase,
compared with precursor virus) (Table 1), emerged from wild-type NAI-sensitive
precursor virus during oseltamivir therapy during the summer months. There was no
molecular variability that would suggest the presence of a mixed population. This was
followed by the rapid emergence of influenza virus with NA gene E119V framework
mutation, which conferred reduced oseltamivir susceptibility (~100-fold decrease),
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compared with precursor virus (Table 1). Viral growth seemed unaffected, as observed
elsewhere [24], because the E119V mutant virus was cultured from the patient’s samples for
6 weeks during oseltamivir therapy and for >4 months after cessation of antiviral therapy
(Figure 1). 
Although amino acid substitutions and subpopulations were detected in HA, NA, and
M2 genes, sequence comparison of the viruses 244 and 260 days after infection with the
precursor virus revealed only 1 fixed nucleotide substitution in both HA and NA genes
(NA gene E119V). In addition, 260 days after the onset of infection in patient 1, the Dutch
2005–2006 influenza epidemic had started, caused by a significantly deviated influenza
A (H3N2) strain. Reinfection with a new influenza A (H3N2) strain is therefore unlikely,
a conclusion further supported by the fact that a single virus sequence was obtained
during the summer, when there was no circulation of influenza virus in the community.
The E119V mutant virus likely retained its pathogenicity during continuous influenza
excretion, illustrated by renewed clinical deterioration to viral lower respiratory tract
infection after a 4-month period of upper respiratory tract infection or no symptoms.
Transient T/A135T/A, A138S, D188N, and N/K189N/K amino acid changes at or near the
HA receptor binding site, compared with precursor virus, may have contributed to
persistence of the E119V variant, partially compensating for potential reduced NA
activity by a decreased HA affinity [25]. HA gene receptor binding site alterations may
emerge and persist more easily among severely immunocompromised patients, with
continuous high-level viral replication and decreased immunogenic selection control
among viruses with aberrant HA antigens. R292K variants appear impaired, as
described elsewhere [24], because this mutation did not persist in the patient and was
possibly selected out by overgrowth of the E119V variant.
In patient 2, a mixed population of NA gene R292K (10%) and NA gene E119V (90%)
mutants with HA gene A138S substitution at the receptor binding site and reduced NAI
susceptibility emerged during oseltamivir therapy and reverted back to wild-type NAI-
sensitive virus after antiviral treatment was discontinued. The emergence of R292K
substitution in viruses from patients 1 and 2, which confers high-level oseltamivir
resistance and reduced zanamivir susceptibility, is of concern because these mutants
hamper therapy with NAIs. Apparently, with selective pressure and lack of immuno-
logical containment, NAI-resistant minor variant viruses can emerge that retain their
replicative ability and evade antiviral therapy. The cessation of oseltamivir therapy
allowed reversion to sensitive wild-type influenza virus A (H3N2) in patient 2, a result
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consistent with prior findings [8,  9] and in contrast to the result observed for patient 1, in
whom the E119V mutation remained fixed after cessation of oseltamivir therapy and
until viral clearance.
None of the patients received adamantane therapy; it was considered unreliable because
of the rapid development of resistance [2,  3]. The M2 protein S31N substitution in viruses
from patients 2 and 3 was not unexpected, because most 2006 national sentinel
influenza A (H3N2) viruses also displayed this amino acid substitution (data not shown).
The detected M2 protein A30S substitution in patient 1 was apparently acquired by
spontaneous mutation and therefore unrelated to exposure, as has been proposed
earlier for the S31N mutation [5]. A30S mutation has been observed in vivo in avian
influenza virus A(H7N2) field isolates [26]. M2 protein mutations at position 30,
conferring amantadine resistance are typically A30V or A30T in humans [27]; we are not
aware of documented A30S mutation in human influenza viruses.
Lymphocytopenia at the time of infection has been documented as an important risk
factor for developing influenza virus pneumonia [20]. In this study, the occurrence of
influenza lower respiratory tract infection in 6 (75%) of 8 patients and the subsequent
fatal outcome in 2 (33%) of 6 patients was similar to the rates of infection and death (80%
and 33%, respectively) reported among severely immunocompromised patients
elsewhere [28]. Clinical improvement of influenza lower respiratory tract infection, in
which it became upper respiratory tract infection or symptoms ceased was significantly
associated with oseltamivir treatment (8 of 8 episodes) compared with untreated
episodes (0 of 2 episodes) (P = .02). During continuous influenza virus excretion, the
remarkable reappearance of specific viral lower respiratory tract infection symptoms
was observed in 4 patients (patients 1, 2, 3, and 8). This affirms the importance of timely
recognition and treatment of influenza lower respiratory tract infection among severely
immunocompromised hosts. 
We conclude that prolonged influenza virus respiratory tract infection is observed
among immunocompromised patients with lymphocytopenia and is associated with
frequent development of influenza lower respiratory tract infection and antiviral
resistance during therapy. PCR-based monitoring for this category of patients should
enable the early detection of influenza viruses and could help prompt the initiation of
timely therapeutic and preventive measures. Lymphocyte reconstitution is associated
with viral clearance, irrespective of receipt of antiviral therapy, a result that warrants
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further exploration of therapeutic approaches that aim to improve specific immune
recovery during prolonged influenza infection. These strategies are important for the
improvement of individual outcomes and for helping to prevent the emergence and
continuous excretion of drug-resistant viruses.
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Abstract
Context: The sudden emergence and rapid spread of oseltamivir-resistant influenza
A(H1N1) viruses with neuraminidase (NA) gene H274Y amino acid substitution is the
hallmark of global seasonal influenza since January 2008. Viruses carrying this
mutation are widely presumed to exhibit attenuated pathogenicity, compromised trans-
mission, and reduced lethality.
Objective: To investigate nosocomial viral transmission in a cluster of patients with
influenza A(H1N1) virus infection.
Design, Setting, and Patients: Descriptive outbreak investigation of 2 hematopoietic
stem cell transplant recipients and an elderly patient who developed hospital-acquired
influenza A virus infection following exposure to an index patient with community-
acquired H274Y-mutated influenza A(H1N1) virus infection in a medical ward at a Dutch
university hospital in February 2008. The investigation included a review of the medical
records, influenza virus polymerase chain reaction and culture, phenotypic oseltamivir
and zanamivir susceptibility determination, and hemagglutinin chain 1 (HA1) gene and
NA gene sequence analysis.
Main Outcome Measure: Phylogenetic relationship of patient cluster influenza
A(H1N1) viruses and other 2007-2008 seasonal influenza A(H1N1) viruses.
Results: Viral HA1 and NA gene sequence analysis from the 4 patients revealed indis-
tinguishable nucleotide sequences and phylogenetic clustering of H274Y-mutated,
oseltamivir-resistant influenza A(H1N1) virus, confirming nosocomial transmission.
Influenza virus pneumonia (3 patients) and attributable mortality (2 patients) during
active infection was observed in patients with lymphocytopenia at onset.
Conclusion: Seasonal oseltamivir-resistant influenza A(H1N1) viruses with NA gene
H274Y mutation are transmitted and retain significant pathogenicity and lethality in
high-risk patients.
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Introduction
A global emergence and rapid spread of oseltamivir-resistant influenza A(H1N1) viruses
carrying a neuraminidase (NA) gene with an H274Y (N2 numbering; H275Y in N1
numbering) amino acid substitution has been observed since January 2008 [1–3]. Viruses
carrying this mutation are presumed to exhibit attenuated pathogenicity [4], compro-
mised transmission [5], and reduced lethality [6]. However, current widespread circu-
lation of oseltamivir-resistant influenza A(H1N1) viruses associated with typical
influenza illnesses and viral pneumonia suggest that these viruses retain significant
transmissibility and pathogenicity [2,  3,  7,  8]. While these resistant variants may cause
significant mortality and retain efficient transmission, these properties have not yet
been firmly established.
Methods
In February 2008, an outbreak of influenza A(H1N1) virus occurred in a medical ward
at a Dutch university hospital. Clinical specimens from symptomatic contact patients
of the presumed index patient were tested by influenza polymerase chain reaction (PCR)
and sequences were further analyzed. Medical records of contact patients with related
influenza virus infection were reviewed for underlying disease, clinical findings, and
outcome. Screening specimens were obtained from contacts of the last outbreak patient
(patient 4) to rule out further spread of the virus. 
Influenza Virus Diagnostics. Influenza virus detection was performed on clinical
respiratory specimens using rapid antigen testing and PCR as described previously [9],
along with viral culture. Antigenic characterization (hemagglutination inhibition
testing) and phenotypic oseltamivir and zanamivir susceptibility (IC50, concentration of
drug needed to inhibit enzyme activity by 50%) were determined as described [10, 11].
Viral RNA extracted from clinical specimens was further transcribed and amplified.
Hemagglutinin chain 1 (HA1) and neuraminidase gene sequences from patients with
confirmed influenza virus infection were analyzed and phylogenetically related to other
2007-2008 seasonal influenza viruses obtained at the hospital or sentinel surveillance
isolates collected nationwide using Bionumerics version 5.1 (Applied Maths, Sint-
Martens-Latem, Belgium). 
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Table 1.   Clinical characteristics of 4 hospitalized patients with oseltamivir-resistant influenza A
(H1N1) virus infection.
Patient 1 (Index) Patient 2 Patient 3 Patient 4
Sex Male Female Male Male
Age, y 47 57 89 66
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a   Determined by olymerase chain reaction (PR). 
b   Lymhocyte count determined 2 to 6 weeks after influenza confirmation.
c   linical diagnosis (dysnea, PR detection of influenza A in resiratory secimens).
d   Pathological diagnosis (histological features, PR detection of influenza A in ulmonary tissue).
Ethical Considerations. The investigation of this outbreak did not involve any planned
activity that could have been reviewed prospectively by an institutional review board or
ethics committee. Nevertheless, all necessary precautions were taken to prevent identi-
fication of the patients and health care workers involved. The physicians involved all
gave signed permission to use clinical data and were informed on the outcome of the
investigation. All of them agreed with the intention to publication. Details including the
age and role of the health care workers were omitted or described in a nonspecific way,
while we also took care to preserve all clinically meaningful details. The chairman of
the ethics committee at the Leiden University Medical Center was consulted retrospec-
tively and agreed to the approach as described for reporting the clinical information
obtained during the investigation and included herein.
Results
Nosocomial Influenza A(H1N1) Virus Outbreak. The clinical characteristics and
timeline of the outbreak of influenza A(H1N1) virus are shown in the Table and in
Figure 1, respectively. Community-acquired oseltamivir-resistant influenza A(H1N1)
virus with NA gene H274Y mutation, isolated from the presumed index case, was
detected in 3 additional patients (mean oseltamivir IC50, 484 nM; mean zanamivir IC50,
1.1 nM). The presumed index case (patient 1), who was vaccinated for 2007-2008 seasonal
influenza and received high-dose (cumulative) prednisolone therapy for systemic lupus
erythematosus, was admitted to the hospital on January 29, 2008, with fever, cough,
dyspnea, and lymphocytopenia. Mechanical ventilation and broad-spectrum empirical
antibacterial treatment were initiated for acute respiratory failure and apparent
pulmonary consolidations by chest radiography. Oseltamivir administration was
initiated following influenza A virus detection using rapid antigen testing and PCR
along with contact and droplet isolation. No other viral and bacterial respiratory
pathogens were detected and blood cultures remained negative. The patient was trans-
ferred to a medical ward following clinical improvement on February 1 and isolation
precautions were continued for the duration of symptoms until February 3. Viral
clearance was confirmed by PCR upon lymphocyte reconstitution in an outpatient
setting on March 4, 2008. Two hematopoietic stem cell transplant recipients (patient 2
and patient 4) and an 89-year-old elderly patient (patient 3) developed hospital-acquired
influenza A virus infection (Table). These patients were present at the same time as the
index patient at the medical ward without isolation procedures (Figure 1), but the 4
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patients never shared rooms. Patient 2 developed mild influenza symptoms with rapid
viral clearance, whereas both patients 3 and 4 developed pulmonary consolidations and
fatal respiratory failure with viral excretion under broad-spectrum antibacterial
therapy. The influenza vaccination status of these patients is not known. The attribution
of mortality to influenza was supported by detection of influenza A(H1N1) viral RNA
from post-mortem pulmonary tissue and histopathological pulmonary findings
consistent with viral pneumonia in patient 4, with the exclusion of other pathogens.
Further nosocomial spread to other contacts within the wards was excluded by PCR.
Figure 1.   Epidemic curve by date of onset of symptoms and timeline of influenza A(H1N1)
nosocomial infections. 
During influenza A(H1N1) virus outbreak, all 4 infected atients were admitted in the same deartment and
never shared rooms. LRTI indicates lower resiratory tract infection; NA, neuraminidase; and URTI, uer
resiratory tract infection.
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Phylogenetic Relationship. HA1 gene and NA gene sequence analysis of viruses from
the 4 outbreak patients revealed indistinguishable nucleotide sequences and phyloge-
netic clustering (Figure 2). In addition to NA gene H274Y substitution, a rare T284A
substitution was sequenced (NA gene sequence GenBank accession numbers AB476754,
AB476755, AB476756, AB462370) and could therefore be recognized as a marker for
transmission. An unlinked national surveillance isolate (A/NL/088/08) with identical
HA1 gene nucleotide sequence revealed no NA gene phylogenetic clustering and lacked
the specific T284A substitution. The NA gene T284A mutation was not observed in other
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Figure 2.   Phylogenetic relationship of nosocomial patient cluster influenza A(H1N1) viruses and
other 2007-2008 seasonal influenza A viruses. 
Influenza A(H1N1) virus HA1 gene sequences obtained from the atient cluster (n=4, marked as hositalized
cluster atient 1, 2, 3, 4) were related to available unlinked 2007-2008 seasonal influenza A(H1N1) viral
sequences obtained at the hosital (n=1, marked as unlinked hositalized atient), surveillance isolates
collected within a 10-km regional zone from the hosital (n=3, marked as regional), nationwide collected
surveillance isolates (n=17, marked as nationwide), and vaccine strain A/Brisbane/59/2007. The HA1 gene
(nucleotides 1-1071) neighbor-joining tree was rooted on vaccine strain A/Solomon Islands/3/2006. Viral
sequence Genbank accession numbers are deicted for hositalized atients.
6
2007-2008 seasonal influenza A(H1N1) viruses or in worldwide sequences submitted to
public databases, reinforcing the unique genetic relatedness of this influenza A(H1N1)
virus patient cluster.
Health Care Workers. Five health care workers developed influenza-like illness (onset
February 4–6, 2008) during admission of the presumed index patient. One health care
worker, vaccinated for the 2007-2008 seasonal influenza, developed influenza-like illness
following established contact with the index patient and continued working. Four other
health care workers took sick leave within 24 to 48 hours of symptom onset. However,
no samples for influenza testing were obtained from any of these 5 health care workers.
Thus, their role in possibly contributing to this apparent nosocomial spread of influenza
could not be confirmed. Viruses cultured from the patient cluster revealed a poor
antigenic match with the 2007-2008 vaccine reference strain A/Solomon Islands/3/06
(approximately 16-fold difference by duplicate hemagglutination inhibition testing). This
may in part explain the sustained susceptibility and infectivity of the vaccinated index
patient and suspected health care worker resulting in the hospital outbreak.
Comment
This outbreak provided evidence that circulating oseltamivir-resistant influenza
A(H1N1) viruses with NA gene H274Y mutation are transmitted between humans.
Limitations of this observational study include the small number of patients, there -
fore the findings require careful interpretation and do not allow conclusions on
the frequency of this complication in hospital settings. The vaccination status of
 secondarily infected cases (patients 2, 3, and 4) remained unclarified. Information on
the mechanism of spread was limited by the circumstances in this study. Data obtained
from clinical specimens suggest different routes of transmission; however, this could
not be further explored because the sampling of symptomatic health care workers
and testing of fomites are not routinely performed. However, analysis of data obtained
from clinical specimens provided some insight to different routes of transmission and
suggested a limited viral spread.
Early identification and prolonged isolation precautions appear prudent in the care for
infected immunocompromised patients to prevent nosocomial influenza virus out -
breaks. This study confirmed that circulating H274Y-mutated A(H1N1) viruses can retain
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significant pathogenicity and lethality, as shown in these elderly or immunocompro-
mised patients with lymphocytopenia, underlining the urgency for the introduction of
new effective antiviral agents and therapeutic strategies [12]. 
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Abstract
The pandemic influenza A (H1N1) 2009 virus (pH1N1) contains novel gene segments of
zoonotic origin that lack virulence and antiviral resistance markers. We aimed to
evaluate the applicability and accuracy of mass spectrometry-based comparative
sequence analysis (MSCSA) to detect genetic mutations associated with increased
virulence or antiviral resistance in pH1N1. During the 2009 H1N1 pandemic, routine
surveillance specimens and clinical antiviral resistance monitoring specimens were
analyzed. Routine surveillance specimens obtained from 70 patients with pH1N1
infection were evaluated for mutations associated with increased virulence (PB1-F2,
PB2 and NS1 genes) or antiviral resistance (neuraminidase gene, NA) using MSCSA and
Sanger sequencing. MSCSA and Sanger sequencing results revealed a high concordance
(nucleotides >99%, SNPs ~94%). Virulence or resistance markers were not detected in
routine surveillance specimens: all identified SNPs encoded for silent mutations or
non-relevant amino acid substitutions. In a second study population, the presence of
H275Y oseltamivir-resistant virus was identified by real-time PCR in 19 of 35 clinical
antiviral resistance monitoring specimens obtained from 4 immunocompromised
patients with ≥14 days prolonged pH1N1 excretion. MSCSA detected H275Y in 24% (4/19)
of positive specimens and Sanger sequencing in 89% (17/19). MSCSA only detected
H275Y when the mutation was dominant in the analyzed specimens. In conclusion,
MSCSA may be used as a rapid screening tool during molecular surveillance of pH1N1.
The low sensitivity for the detection of H275Y mutation in mixed viral populations
suggests that MSCSA is not suitable for antiviral resistance monitoring in the
clinical setting.
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Introduction
Influenza A and B viruses cause seasonal epidemics of febrile respiratory illness in the
human population. The negative-sense RNA genome of influenza A viruses consists
of eight segments which encode at least 13 proteins following tran scription and trans-
lation [1–3]. Seasonal epidemics arise by antigenic drift through frequent mutations in
hemagglutinin (HA) and neuraminidase (NA) surface glycoprotein genes enabling
seasonal host immune evasion by the virus. In rare occasions, human influenza A virus
gene segments re-assort with other influenza A viruses from avian, human, and swine
origins which can result in new antigenic subtypes that may cause severe human
influenza pandemics [4].
In 2009, the influenza A (H1N1)pdm09 virus (pH1N1) with a relatively new antigenic
subtype of zoonotic-origin emerged in Mexico and caused an influenza pandemic
followed by rapid global spread in the human population [5–7]. The virus was likely
generated through multiple reassortment events in pigs, and contained gene segments
from North American ‘‘classical’’ swine influenza virus A/H1N1 (HA, NP, NS), North
American avian influenza virus A/H1N1 (PB2, PA), human seasonal influenza virus
A/H3N2 (PB1) and Eurasian swine influenza virus A/H1N1 (M, NA) [8]. The overall clinical
presentation in humans appeared unexpectedly mild which can not be explained by
residual host immunity in the human population. A minority of children and
adults had preexisting cross-protective antibody titers against pH1N1 [9]. Only ~18% of
influenza A CD8+ cytotoxic T lymphocyte epitopes derived from previous seasonal
influenza A viruses are conserved in pH1N1 [10]. The novel pH1N1 virus contained gene
segments of zoonotic origin that lack virulence and antiviral resistance markers due to
favorable genetic polymorphisms or truncations in PB2, PB1-F2, NS1 and NA genes [11– 14].
Novel adaptive mutations may emerge in PB2, PB1-F2 and NS1 genes with the potential
to increase viral replication and host pathogenicity of pH1N1 [14–16]. In addition,
oseltamivir-resistant virus may emerge during selective pressure [17,  18]. 
Wide-scale molecular surveillance is warranted but conventional sequencing methods
are laborious and inefficient. Mass spectrometry-based comparative sequence analysis
(MSCSA) enables rapid multi-genomic sequence analysis with automated data analysis
and could improve the availability of relevant pH1N1 genomic sequences [19,  20]. Rapid
identification of relevant pH1N1 mutations in the community or in clinical settings may
guide early prevention and intervention strategies. MSCSA was previously successfully
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used for the analysis of human cytomegalovirus sequence polymorphisms in UL97 gene
and for detection of genetic mutations associated with antiviral resistance in clinical
specimens [19]. In this study, we evaluated the applicability and accuracy of MSCSA to
detect pH1N1 genetic mutations associated with increased virulence (PB1-F2, PB2 and
NS1 genes) or antiviral resistance (NA gene).
Methods
Active Case Finding and Ethics Statement. During the 2009 H1N1 pandemic,
human pH1N1 infection cases became obligatory notifiable by law in the Netherlands
on 29th April 2009 (RIVM website. Available: www.rivm.nl/bibliotheek/rapporten/
215011006. pdf;  access verified March 3rd, 2013). A nationwide case definition was deter-
mined based on the European Union case definition [21] and contained clinical and
epidemiological criteria upon which routine diagnostic testing was indicated and sub -
sequent control measures could be applied. Diagnostic specimens were obtained from
suspect cases by municipal health services, general practitioners or hospitals following
influenza pandemic procedures from the National Institute of Public Health and the
Environment (RIVM) responsible for the control of infectious diseases. In the region of
Leiden, the first pandemic wave (weeks 27 through 35) inferred a normal (Gaussian)
distribution of which the peak occurred in week 31 when 72% of positive patients were
observed (Figure 1). All specimens included in this study were collected in the region of
Leiden for routine influenza diagnostic testing following national pandemic proce-
dures. The specimens were sent directly to the regional reference outbreak assistance
laboratory accompanied by a written diagnostic request from the responsible phyci -
sians and results were reported back to the medical facility who requested them. After
performing routine influenza diagnostic testing, the reference outbreak assistance
laboratory evaluated the additional presence of virulence and resistance markers
for technical and epidemiological reasons. Additional influenza molecular characteri-
zation was not considered to be fully part of the initial diagnostic request, therefore all
specimens were anonymized for precautionary reasons after receiving them from the
requesting medical facilities and phycisians. There was no access to patient identifying
information or clinical data during additional molecular characterization following
ethical principles expressed in the Declaration of Helsinki. Approval from the institu-
tional review board and the use of informed consents were not necessary for influenza
diagnostic testing on specimens sent to the laboratory for this specific purpose.    
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Study Populations. Two study populations with pH1N1 infection are under evaluation
in this study. Routine surveillance specimens were obtained from 344 suspect cases in
the region of Leiden during the early phase of the 2009 H1N1 pandemic (June 29th
through August 30th, 2009) and submitted to the regional reference outbreak assistance
laboratory at Leiden University Medical Center. Influenza A virus was detected in 75
specimens (70 pH1N1, 4 seasonal H1N1, 1 seasonal H3N2). A total of 70 specimens from
70 patients with pH1N1 infection (43 male; median age 21 years, range 1 to 63 years) were
included in this study. A second collection of 35 clinical antiviral resistance monitoring
specimens was obtained from hospitalized immunocompromised patients with ≥14 days
prolonged pH1N1 excretion (panH1 Ct values ≤37.0) during widespread pH1N1 circu-
lation (November 3rd 2009 through January 13th, 2010). Real-time PCR confirmed H275Y
mutated virus in 19 of 35 specimens obtained from 3 of 4 immunocompromised patients
and these results were compared to MSCSA and Sanger sequencing findings of the NA
gene.
Figure 1.   A graphic representation of the first wave of the 2009 H1N1 pandemic in the region of
Leiden (The Netherlands).
Influenza A Virus Detection and Molecular Typing. RNA was extracted from clinical
specimens using the automated MagNA Pure nucleic acid isolation system (Roche
Diagnostics, Almere, The Netherlands). Influenza A virus screening was performed
by real-time PCR using InfA primers and a probe targeting the matrix gene and
following procedures validated by the World Health Organization (WHO) and
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website: http:// www.who.int/csr/resources/publications/swineflu/CDCrealtimeRTPCR
protocol_20090428.pdf; access verified March 3rd, 2013). The presence of pH1N1 was
confirmed by PCR using panH1 and MexFluN1 protocols targeting the HA and NA
genes [22,  23]. Influenza A virus specimens that were negative for pH1N1 were evaluated
for seasonal influenza A (H1N1) and A (H3N2) viruses using H1-RF and H3-RF protocols
targeting the HA gene [24] (http://www.who.int/csr/resources/publications/swineflu/ WHO_
Diagnostic_ RecommendationsH1N1_20090521.pdf; access verified March 3rd, 2013).
MSCSA, Sanger Sequencing and H275Y Real-time PCR. MSCSA and Sanger
sequencing were performed on all specimen collections containing influenza A virus,
whereas H275Y real-time PCR was only carried out on the clinical antiviral resistance
monitoring specimens after which H275Y positive findings were correlated to MSCSA
and Sanger sequencing results. H275Y real-time PCR was performed as described previ-
ously [22]. MSCSA using the MassARRAY/iSEQTM – Comparative Sequence Analysis
technique (Sequenom, San Diego, USA) is based on the PCR amplification of a genomic
target and in vitro transcription to produce RNA strands. These transcripts are cleaved
to produce a sequence-specific set of fragments for analysis by mass spectrometry [20].
As the MSCSA protocol starts from DNA, a reverse transcription reaction using
SuperScriptII (Invitrogen) with random primers (Promega; 1 mg final concentration;
incubations at 25 ˚C for 10 min, at 40 ˚C for 90 min and 70 ˚C for 15 min) was
 implemented prior to PCR amplification. We designed T7 promoter-tagged (CAGTAAT-
ACGACTCACTATAGGGAGAAGGCT) forward primers and SP6-tagged (CGATTTAGGTGA-
CACTATAGAAGAGAGGCT) reverse primers for the specific amplification of NA, PB1-F2,
PB2 and NS1 targets (Table 1). The pH1N1 primers were designed to cover potential
markers of virulence (PB2 gene positions 271, 590, 591, 627, 701; PB1-F2 gene position 66;
NS1 gene positions 227–230), protein segment truncation (PB1-F2 gene positions 12, 58,
88; NS1 gene position 220) and antiviral resistance (NA gene positions 116, 117, 119, 136,
150, 151, 199, 223, 275 and 295) in the viral genome (Table 2) [11–14,  25,  26]. PCR amplification
of the targets was performed using 2 μl of RT product, with the tagged primers in 10 μl
volume in 384 well plates as previously described [19]. The sample was processed by
shrimp alkaline phosphatase treatment, in vitro transcription, and C- or U-specific
RNaseA cleavage, according to the manufacturer’s instructions and using a MassARRAY
Liquid Handler (Matrix+FusioTM Chip Module, Sequenom). The fragments resulting
from RNA cleavage were diluted in double-distilled water and desalted with Clean Resin
(Sequenom), transferred to a SpectroCHIP array (Sequenom), and analyzed by matrix-
assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry
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(MassARRAY Compact Analyzer, Sequenom). Sanger sequencing was done on 2 μl of the
PCR amplified products that were produced during the MSCSA procedure. Sanger
sequencing reactions were performed in a volume of 10 μl using Big Dye terminator v 1.1
with sequencing buffer (Applied Biosystems) and 1 mM primer. The primers for Sanger
sequencing were identical to the primers used for MSCSA (Table 1), but without the T7-
and SP6-containing tails. Nucleotide sequence analysis was performed on an ABI Prism
3100 Genetic Analyser (Applied Biosystems).
Table 1.   Overview of pH1N1 Sanger sequencing and MSCSA primers and amplicon sizes.
Table 2.   Surveillance of pH1N1 genetic markers associated with virulence or antiviral resistance.
Data Analysis. For MSCSA, the mass spectra of four amplicon transcript cleavage
products per sample were matched against cleavage patterns calculated from an imported
set of reference sequences [20]. The reference database was created by the authors and
included a set of 193 NA gene, 67 PB2 gene, 210 NS1 gene and 53 PB1-F2 gene sequences
imported from a resource database in September 2009 (PubMed website. Available:
http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html; access verified September 3rd, 2009).











NA Flu-NA_F (274) $ tgccctgttagtggatggc Flu-NA_SP6R (988) # cattagggcgtggattgtctc 715 B
PB1-F2 Flu-PB1-F2_F (1) $ atggatgtcaatccgactctac Flu-PB1-F2_SP6R (476) # tcattagctgttaggccattcg 476 B
PB2 Flu-PB2_F (1764) $ cagaagccggtacagtggattc Flu-PB2_SP6R (2201) # accaacactacgtccccttgc 438 B
NS1 Flu-NS1_F (211) $ cttgaaagaggaatccagcgag Flu-NS1_SP6R (740) # caatctgtgccgcatttcttc 530 B
B, base airs.
$ 5’   osition of the first nucleotide of the forward rimer in the corresonding gene. 
# 5’   osition of the last nucleotide of the reverse rimer in the corresonding gene. 
Gene Antiviral resistance Increased virulence Protein truncation
NA V116, I117, E119, Q136, K150, D151, D199, I223, H275, N295 none none
PB1-F2 none N66 Sto12, Sto58, Sto88
PB2 none A271, S590, R591, E627, D701 none
NS1 none G227, T228, E229, I230 Sto220
Relevant amino acid genetic ositions are deicted for each corresonding gene.
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sequences. MSCSA and Sanger sequences were aligned to influenza A/ Califor nia/ 04/2009
(H1N1) and single nucleotide polymorphisms (SNPs) were defined as nucleotide variations
to this reference sequence.
Results
MSCSA Primers and Amplicons. Primers utilized for MSCSA were specific for pH1N1
as they did not amplify seasonal influenza A(H1N1 or H3N2). Among 70 routine surveil-
lance specimens, the primers amplified 265 of in total 280 amplicons (95%) including NA
(63/70), PB1-F2 (65/70), PB2 (68/70) and NS1 genes (69/70). PCR amplification of PB1-F2,
PB2 and NS1 genes only failed in specimens with low viral levels (mean InfA PCR Ct
36.2), whereas amplification was observed in specimens containing high viral levels
(mean InfA PCR Ct 26.5). The amplification of the NA gene failed in 4 specimens with
high viral levels (range Ct 22.3 to 28.1), suggesting that occasionally the primer sequence
did not correspond to the actual viral sequence.
MSCSA and Sanger Sequencing of Routine Surveillance Specimens. Using the
resource database in September 2009 as reference database for MSCSA, 99.9% of the total
number of nucleotides (n= 130204) matched between both methods. A total of 93.6%
(456/487) of all SNPs were identified by both methods (Table 3). More accurate results
were obtained for the NA, PB2 and NS1 amplicons (93.2%, 98.7% and 90.1%, respectively)
compared to the PB1-F2 amplicon (82.9%). In a small number of cases, a SNP detected by
both methods could not be pinpointed to an exact position within an eleven nucleotide
region by MSCSA (17/487, 3.5%). These inconclusive sequence data resulted in <0.1%
uncertain nucleotide positions and were not considered as mismatches. A high degree of
concordance was observed for the detection of SNPs via MSCSA and Sanger sequencing.
The majority of SNPs (246/456) resulted in silent mutations and few SNPs (210/456)
encoded for non-relevant amino acid substitutions in NA gene (V106I (n= 61), V203M
(n = 1), N248D (n= 62), S286G (n =1)), PB1-F2 gene (T34A (n= 1), V113A(n = 1)), PB2 gene
(K660R (n =2)) and NS1 gene segments (I123V (n= 61), N133D (n= 16), S135N (n= 1), G154R
(n= 1), V194I (n= 1), D207N (n = 1)). The degree of discordance was limited (31/487 SNPs)
and only 8 amino acid substitutions differed among the results generated by MSCSA
and Sanger sequencing. We detected no mutations associated with increased virulence
or with reversion of protein segment truncation by either method. All surveillance
specimens had wild-type sequences in virulence markers (PB2 gene A271, S590, R591,
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E627, D701; PB1-F2 gene N66; NS1 gene G227, T228, E229 and I230) and stop codons in
protein truncation markers (PB1-F2 stop12, stop58, stop88; NS1 gene stop220). MSCSA
and Sanger sequencing detected no mutations associated with antiviral resistance (NA
gene V116, I117, E119, Q136, K150, D151, D199, I223, H275 and N295).
Table 3.   MSCSA and Sanger sequencing of 70 pH1N1 virus specimens.
Clinical Antiviral Resistance Monitoring Specimens. Oseltamivir-resistant H275Y
mutated virus was confirmed in 19 of 35 specimens clinical antiviral resistance
monitoring specimens by H275Y real-time PCR and these findings were compared to
MSCSA and Sanger sequencing results. MSCSA detected NA gene H275Y mutation in 4
of 19 samples (24%) while the mutation was observed in 17/19 samples by Sanger
sequencing (89%). MSCSA detected NA gene H275Y mutation in specimens with fully
mutant virus populations (4/4) but not in specimens with mixed wild-type and mutant
populations (0/15). By visual evaluation of NA gene mass spectrometry spectra, the
presence of peaks derived from the wild type sequence as well as from the H275Y-
associated mutation were observed in many samples. In this way, we were able to infer
the presence of H275Y minor populations in 14 pH1N1 samples, which led to a 95% corre-
spondence between MSCSA and real-time PCR (18 of 19 samples).
Target Evaluation Total NA gene PB1-F2 gene PB2 gene NS1 gene
Nucleotides Genetic sequence 130204 42525 27216 26860 33603
Match (%) # 130173 (99,98%) 42512 (99,97%) 27210 (99,98%) 26858 (99,99%) 33593 (99,97%)
Amlicons Genetic sequence 263 63 63 $ 68 69
Match (%) # 239 (90,9%) 54 (85,7%) 58 (92,1%) 66 (97,1%) 61 (88,4%)
SNPs Genetic sequence 487 192 35 154 106
Match (%) # 456 (93,6%) 179 (93,2%) 29 (82,9%) 152 (98,7%) 96 (90,1%)
SNPs in MSSA 1 13 8 0 0 5
SNPs in Sanger 2 18 5 6 2 5
$   Sanger sequencing was succesful in 63 of 65 secimens determined by MSSA.
#   Sequence match using MSSA and Sanger sequencing.
1   SNPs in MSSA and not in Sanger sequencing;
2   SNPs in Sanger and not MSSA.
Molecular surveillance of influenza A(H1N1)dm09 virus |  115
7
Discussion
Molecular surveillance of human influenza viruses is important to monitor viral
evolution. Genetic mutations occur frequently due to the lack of proofreading by the
influenza virus RNA polymerase and may emerge during recurrent interspecies trans-
mission or wide-scale antiviral selective pressure [1,  7,  14–17]. Rapid identification of
relevant mutations associated with increased virulence or antiviral resistance during
active surveillance of pH1N1 may guide early prevention and treatment strategies.
MSCSA enables medium- to high-throughput genetic sequence analysis of amplified
targets of genomic DNA or RNA with automated data analysis [20]. During the 2009 H1N1
pandemic, we evaluated influenza A-positive routine surveillance specimens for
virulence or resistance markers using MSCSA and Sanger sequencing and included
H275Y real-time PCR on clinical antiviral resistance monitoring specimens. MSCSA did
not cover the complete pH1N1 genome since we chose to focus on gene segments
(Table 2) that contain relevant virulence or resistance markers (with the exception of the
HA gene) [11–14,  25,  26].
We observed a high concordance between MSCSA and Sanger sequencing (nucleo tides
>99%, SNPs 93.6%) in 70 routine surveillance specimens and detected 487 SNPs. Most
SNPs encoded for silent mutations and few encoded for non-relevant amino acid
changes compared to reference influenza A/California/04/2009 (H1N1) virus. The most
frequently detected non-relevant amino acid changes in the NA gene (V106I (n = 61),
N248D (n = 62)) and NS1 gene segments (I123V (n = 61), N133D (n = 16)) are well described
by others [27]. Genetic mutations associated with increased virulence (PB2 gene positions
271, 590, 591, 627, 701; PB1-F2 gene position 66; NS1 gene positions 227–230), reversion of
protein segment truncation (PB1-F2 gene positions 12, 58, 88; NS1 gene position 220)
or antiviral resistance (NA gene positions V116, I117, E119, Q136, K150, D151, D199,
I223, H275 and N295) were not detected by either method in routine surveillance
specimens [11– 14,  25,  26]. Amino acid replacement at residue S334 associated with
increased oseltamivir resistance was not monitored in the NA amplicon. This is not of
great concern because mutations at amino acid S334 can only increase oseltamivir
resistance in the presence of H275Y mutation but does not lead to phenotypic antiviral
resistance by itself [26]. Genetic sequences of pH1N1 circulating in the region of Leiden
appeared genetically stable, similar to pH1N1 during the early phase of the 2009 H1N1
pandemic in Mexico and the United States [7]. MSCSA could not accurately pinpoint the
exact position of a small number of SNPs in spite of the reference database. Relevant
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SNPs detected by MSCSA always need to be confirmed by Sanger sequencing, pyrose-
quencing or real-time PCR to limit potential misinterpretations during molecular
surveillance. We emphasize that the reference database must be continuously updated
with recent virus sequences for MSCSA to remain accurate. The MSCSA reference
database has not been updated since the 2009 H1N1 pandemic, therefore newer versions
of the reference database were not available to re-analyze the data.
Influenza reverse transcription-polymerase chain reaction/electro-spray ionization (RT-
PCR/ESI-MS) assay is a similar mass spectrometry-based auto mated method which is
capable of measuring amplicon-derived masses. The benefit of MSCSA over RT-PCR/ESI-
MS is the possibility to analyze larger amplicon sizes (500–800 versus 150 nucleotides)
and its capability to detect all nucleotide variations within the analyzed target region
rather than providing genomic signatures [28,  29]. Some methods for antiviral resistance
detection, like real-time PCR, are fast, but only allow for the analysis of fixed genome
positions known to be involved in antiviral drug resistance.
In this study, a second collection of clinical antiviral resistance monitoring specimens
was included and real-time PCR detected oseltamivir-resistant H275Y mutated virus
in 19 of 35 specimens obtained from 3 of 4 immunocompromised patients. We detected
no other mutations that are associated with antiviral resistance including NA gene
positions V116, I117, E119, Q136, K150, D151, D199, I223 and N295 [25,26]. Previous
influenza studies have shown that immunocompromised patients with prolonged viral
excretion are at increased risk for developing neuraminidase inhibitor-resistant virus
during continued oseltamivir treatment [30,  31]. Frequent development of antiviral-
resistant viruses among 3 of 4 (75%) immunocompromised patients is in agreement
with previous studies [32–34]. MSCSA detected H275Y in 24% (4/19) of positive
specimens and Sanger sequencing in 89% (17/19). MSCSA only detected H275Y
when the mutation was dominant in the analyzed specimens. The ability to infer the
presence of H275Y (18 of 19 samples) by visual evaluation of the mass spectrometry
spectra indicated that iSEQ software improvement may result in improved detection
of minor variants in mixed populations. However, pyrosequencing and real-time
PCR currently remain the designated methods for continued antiviral resistance
monitoring in clinical settings [22,  25].
In conclusion, MSCSA may be used as a rapid screening tool to monitor fixed nucleotide
changes and potential virulence markers in the pH1N1 genetic background. MSCSA does
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not seem applicable for continued antiviral resistance monitoring in the clinical setting
since detection of the H275Y mutation was limited by a very low sensitivity in the
presence of minor variants and mixed genotypes.
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Introduction
Hematology-oncology patients can develop remarkably prolonged influenza virus
excretion with an enigmatic wide clinical spectrum [1–6]. These patients often develop
mild virus-associated symptoms and occasional bacterial or fungal pneumonic coinfec-
tions, but significant numbers of cases develop severe influenza virus-associated lower
respiratory tract infection (LRTI) and acute respiratory distress syndrome (ARDS).
Risk factors for influenza LRTI include profound lymphopenia, lack of early antiviral
treatment and old age [5,  6]. Pathogenesis of severe viral LRTI and ARDS is unclear
and may include virus-induced pathology or excessive immunopathology [7]. Impaired
influenza-specific host immune responses are well-established in hematology-
oncology patients but surprisingly little is known about the interactions with virus-
associated clinical manifestations and outcomes. The recent introduction of influenza A
(H1N1)pdm09 virus in the human population with limited preexistent immunity
provided the opportunity to evaluate the role of innate and adaptive host immune
findings in determining virus-specific symptoms and viral clearance among hematology-
oncology patients with prolonged viral excretion.
Methods
Patients. In this observational study, adult hematology-oncology patients hospitalized
with ≥14 days prolonged A(H1N1)pdm09 virus excretion between November 2009 and
April 2013 were eligible for inclusion. The institutional review board approved the pre-
established study protocol and informed consent forms that were obtained from all
subjects. Patients or legal representatives signed informed consent for voluntary study
participation and confidentiality. Permission was granted for clinical data collection,
blood draw of a research specimen and immunologic studies. Exclusion criteria were
patients aged < 18 years, patients deemed unfit by the treating physician (for example,
owing to severe underlying bleeding disorders, religious background including Jehova’s
witnesses, altered mental or emotional status) and patients or legal representatives not
wishing to enter the study. 
Clinical data and virus diagnostics. Medical records were reviewed for relevant
clinical findings, virus-associated symptoms and outcomes. Respiratory specimens were
assessed for A(H1N1)pdm09, neuraminidase gene H275Y mutation encoding oseltamivir
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resistance and other respiratory viruses using real-time PCR and viral culture [8].
Pulmonary imaging (chest radiography or computed tomography), bronchoalvolar
lavage microbiology results and broad-spectrum antimicrobial treatment regimens
were evaluated to confirm severe A(H1N1)pdm09- associated LRTI and ARDS requiring
invasive mechanical ventilation and to exclude concomitant infections (viral, bacterial
or fungal) and non-infectious cardiopulmonary causes (lung embolism, pneumothorax
or congestive cardiac failure). Influenza A (H1N1)pdm09 virus isolates were routinely
cultured in established lines of monkey kidney cells (LLCMK2) and Madin-Darby canine
kidney cells and further characterized using duplicate hemagglutinin inhibition (HI)
tests to confirm antigenic similarity with the corresponding vaccine strain. 
Humoral and cell-mediated immune responses. Humoral responses were deter-
mined against homologous virus and reference A/California/007/09 vaccine strain
using serum duplicate HI tests, turkey erythrocytes and four hemagglutinin units of
virus. Seroconversion was defined as a fourfold rise of HI titers and HI titers ≥80 were
considered seroprotective. White blood cell differential counts were evaluated.
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centri -
fugation and lymphocyte subsets were quantified by flow cytometry using CD3, CD4,
CD8, CD16, CD19 and CD56 fluorochrome-labeled antibodies [9]. Minimum absolute cell
count references were defined for granulocytes (500/mm3), monocytes (100/mm3),
lymphocytes (1000/mm3), CD3+CD4+ (560/mm3) T cells, CD3+CD8+ (260/mm3) T cells,
CD3−CD16+ and/or CD56+ nature killer (NK) cells (40/mm3) and CD19+ B cells (60/mm3).
T-cell counts ≤20% of minimum reference were defined as profound T-cell lympho -
penia [10]. Defined surrogate antibody-dependent cell-mediated cytotoxicity (ADCC)
markers included the combined presence of seroprotective HI titers with CD16+ FcIgG
receptor-bearing cytotoxic NK cells and monocytes in blood. The presence of virus-
specific T cells was evaluated by flow cytometry. In brief, thawed PBMCs were stimu-
lated with conserved peptides derived from the nucleoprotein and M1 protein, live
influenza A/Netherlands/602/09 (H1N1)pdm09 virus or reference strain Resvir-9 (H3N2),
1 µg/ml Staphylococcus enterotoxin B (SEB; Sigma-Aldrich, Zwijndrecht, the Nether -
lands), or left untreated. The cells were permeabilized and incubated with anti -
bodies directed against differentiation (CD3, αCD3 PerCP BD Biosciences (Breda, The
Netherlands) # 345766; CD4, αCD4 Pacific blue BD Biosciences # 558116; CD8, αCD8 PECy7
eBioscience # 25-0088-42), activation (CD69, αCD69 APC BD Biosciences # 340560) and
intracellular cytokine expression (IFNγ, αIFN-γ FITC eBioscience (Vienna, Austria) # 11-
7319-82) markers and analyzed by flow cytometry (~ 1 ×106 cells per sample). Dead cell
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staining excluded cells with non-specific results. SEB was used as a positive control
and to monitor functional integrity of T cells. Functional virus-specific T cells were
confirmed by duplicate detection of CD3+CD4+CD69+IFNγ+ or CD3+CD8+CD69+IFNγ+
cells [9,  11], excluding profound T-cell lymphopenia. Virus- and SEB-specific T cells were
calculated by subtracting CD4+IFNγ+ and CD8+IFNγ+ cell percentages observed after
incubation with medium only.
Results
Enrolled patients. Six adult hematology-oncology patients (age, range 39–67 years)
hospitalized with prolonged A(H1N1)pdm09 excretion (duration, 29 to >90 days) were
enrolled (Figure 1a). Patient 1 (cutaneous T-cell lymphoma) and patient 2 (acute undif-
ferentiated leukemia) received immunosuppressive agents for the prophylaxis or
treatment of GvHD following allogeneic hematopoietic stem cell transplantation (allo-
HSCT) 7 and 22 months earlier. Patient 3 (chronic lymphocytic leukemia) received high-
dose steroids for leukemic hyperleukocytosis. Pre-allo-HSCT conditioning regimens
were provided to patient 4 (progressive multiple myeloma), patient 5 (refractory T-cell
non-Hodgkin lymphoma) and patient 6 (refractory B-cell non-Hodgkin lymphoma).
Never was the decision taken to proceed with allo-HSCT during any knowledge of active
A (H1N1)pdm09 infection. Four patients received a well-matched influenza vaccine
(patients 1, 3, 4 and 5) during the corresponding season but had no seroprotective HI Ab
titers during onset (Figure 1b). Oseltamivir or zanamivir antiviral treatment was
provided to all patients (n=2, ≤48 h; n=4, >48 h). Four patients developed H275Y resistant
virus (Figure 1a) and variable clinical outcomes (2 mild, 2 severe).
Prolonged A(H1N1)pdm09 virus excretion. All six patients displayed prolonged
viral excretion during CD4+ and CD8+ T-cell lymphopenia (Figure 2a). Virus excretion
duration was not influenced by antiviral treatment, seroprotective HI titers (Figures 1a,
1b) or ADCC markers (data not shown). 
Virus-associated symptoms. The six patients developed a wide spectrum of virus-
associated symptoms ranging from mild URTI to severe LRTI and ARDS (Figure 1a).
Intercurrent pulmonary co-infections and non-infectious cardiopulmonary diagnoses
(congestive cardiac failure, pneumothorax) were excluded or effectively treated and did
not seem to confound virus-associated measures. Two cases (patients 1 and 2) displayed
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mild symptoms during the presence of CD8+ T cells (Figure 2a). Mild symptoms of
patient 1 completely alleviated in the presence of ADCC markers whereas patient 2
manifested sustained mild bronchitis and recurrent Haemophilus influenzae broncho -
pneumonia during absence of seroprotective antibodies. Four cases (patients 3, 4, 5 and
6) developed severe viral LRTI during profound CD4+ and CD8+ T-cell lymphopenia
(Figures 1a, 2a) and intercurrent combined absence of ADCC markers. The onset of
severe viral LRTI and ARDS during profound CD4+ and CD8+ T-cell lymphopenia
coincided with innate cell-mediated immune reconstitution in all four patients
Figure 1.   (a) Timeline of prolonged A(H1N1)pdm09 virus infection and antiviral treatment. 
(b) Humoral responses during A(H1N1)pdm09 virus infection. 
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(Figure 2b). Patients 4, 5 and 6 manifested granulocyte, monocyte and NK cell reconsti-
tution after recent allo-HSCT and patient 3 displayed granulocyte reconstitution during
leukemic hyperleukocytosis.
Viral clearance. Complete viral clearance occurred strictly during CD4+ and CD8+
T-cell reconstitution and functional virus-specific T-cell responses (Figure 2a)
in patient 1 (CD3+CD4+CD69+IFNγ+ 0.02%; CD3+CD8+CD69+IFNγ+ 0.12%), patient 3
(CD4+CD69+IFNγ+ 0.47%; CD3+CD8+CD69+IFNγ+ 0.20%) and patient 4 (CD4+ T-cell recon-
stitution with homologous virus seroconversion and emergence of CD8+ T cells).
Discussion
The findings from this study confirm that influenza virus-infected hematology-oncology
patients develop a wide clinical spectrum ranging from mild [1] to severe respiratory
symptoms [2–4] during prolonged viral excretion. Innate and adaptive host immune
responses appear to be major determinants of virus-associated outcome and viral
clearance [3,  6,  7]. Earlier studies report that undefined lymphopenia increases the risk
for prolonged influenza virus excretion [5,  6] and that lymphocyte reconstitution is
associated with viral clearance [3]. Our findings show that prolonged viral excretion more
specifically correlated with T-cell lymphopenia. It is generally assumed that T cells
induce viral clearance [7], but this has not clearly been demonstrated in human influenza
cases. The role of CD8+ T cells has frequently been characterized in influenza animal
models but the role of CD4+ T cells remains unclear [12]. We confirm that viral clearance
occurs during CD4+ and CD8+ T-cell reconstitution in the presence of functional virus-
specific T cells (Figure 2a). Viral clearance did not occur during pro found CD4+ T-cell and
CD8+ T-cell lymphopenia (patients 5 and 6) or during profound CD4+ T-cell lymphopenia
with a low-level CD8+ T-cell count (patient 2). This observation supports the assumption
that both CD4+ and CD8+ T-cell responses determine complete viral clearance [12]. 
The wide clinical spectrum among six hematology-oncology patients with prolonged
influenza virus excretion prompted an investigation into the protective role of host
immune responses and pathogenesis. Mild symptoms (patients 1 and 2) correlated with
a low-level presence of CD8+ T cells even during absence of seroprotective HI titers
(patient 2). In contrast, severe viral LRTI (patients 3, 4, 5 and 6) manifested during
profound CD4+ and CD8+ T-cell lymphopenia and intercurrent absence of ADCC markers
128 |  hater 8
Host immune resonses dictate influenza outcome in hematology-oncology atients |  129
8
Figure 2.   (a) T- and B-cell counts during prolonged A(H1N1)pdm09 virus infection and final outcome.
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even during the presence of seroprotective HI titers (patients 3 and 4). Patients 3 and 4
developed seroprotective HI titers despite transient profound CD4+ T-cell lymphopenia.
High virus-specific Ab titers did not prevent the development of severe viral LRTI and
ARDS probably due to intercurrent absence of ADCC effector cells. Altogether, these
results support the hypothesis that CD8+ T cells independently mediate clinical
protection [7,  11] and that ADCC provides additional clinical protection [13]. The patho-
genesis of severe influenza LRTI and ARDS remains unclear and is likely multifactorial.
Four cases (patients 3, 4, 5 and 6) with (transient) profound T-cell lymphopenia and
absence of ADCC markers developed severe virus-associated LRTI and ARDS during
innate cell reconstitution. Our findings suggest that profound CD4+ and CD8+ T-cell
lymphopenia and (transient) absence of ADCC markers may have provided a window of
opportunity for the virus to reach lower alveolar compartments and trigger severe
immunopathology by the excessive influx of neutrophils and macrophages [14]. Timely
antiviral treatment is therefore important when protective immune responses are still
lacking and early IV zanamivir therapy may benefit patients who are most at risk [15].
Study limitations include a small sample size due to the rare occurrence of prolonged
influenza virus excretion, which does not permit statistical analysis. Additional limita-
tions include technical difficulties of measuring T-cell and ADCC responses, unblinded
clinical and outcome assessments by the clinical investigator and incomplete detection
of existing antiviral resistance mutations. Despite these limitations, the study provides
new insights into the role of host immune responses in determining influenza infection
outcomes. Our findings underline the importance of influenza prevention strategies in
hematology-oncology patients and show that vaccine improvements are needed to raise
immunogenicity in this vulnerable patient group.
In conclusion, prolonged influenza virus excretion is associated with T-cell lympho -
penia in hematology-oncology patients. CD8+ T cells and ADCC markers afford clinical
protection and combined CD4+ and CD8+ T-cell responses mediate viral clearance.
Pathogenesis of severe viral LRTI and ARDS is likely the result of virus reaching lower
compartments of the lung during a lack of combined T-cell- and ADCC-mediated
immunological protection followed by excessive immunopathology triggered by innate
cell-mediated responses. More insight into the role of influenza host immune responses
can improve the clinical management of infected hematology-oncology patients and
may limit the emergence of antiviral-resistant viruses.
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Human influenza viruses have caused significant pandemics and epidemics throughout
history and continue to be a relevant health problem in humans. These viruses express
a remarkable genomic and antigenic plasticity due to high mutation rates and evade
host immunity through rapid antigenic drift. Influenza clinical studies are thriving due
to the availability of new powerful molecular diagnostic tools and the recent emergence
of a novel pandemic strain and antiviral-resistant viruses. Molecular techniques are
essential to increase our knowledge on virus characteristics, clinical manifestations,
and host-pathogen interactions in a growing number of high-risk patients. In the next
paragraphs, we summarize and discuss our findings on the implementation and clinical
evaluation of different molecular methods intended for the rapid detection and genetic
characterization of influenza virus infections and outbreaks in the clinical setting. We
evaluated virus excretion duration, antiviral resistance development, and host immune
responses in determining virus-associated symptoms and outcome in hematology-
oncology patients. 
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Molecular diagnosis of respiratory virus infections
in children
The studies in chapters 2 and 3 concern the clinical evaluation of influenza and other
respiratory viruses in children using molecular diagnostic methods. Respiratory virus
infections are the most important cause of morbidity in children worldwide [1– 3].
Influenza signs and symptoms were previously defined using conventional diagnostic
methods in hospitalized children and are therefore limited towards sampling and
disease severity. New molecular tools provide the opportunity to re-evaluate the occur-
rence and clinical spectrum of different respiratory viruses including influenza viruses.
In chapter 2, we used multiplex real-time PCR to investigate the relative incidence of
respiratory virus infections in children sampled ≤48 hours of hospital presentation and
evaluated virus-specific clinical correlations in young children. We confirmed the
results of other recent molecular studies that showed a high incidence of respiratory
viruses in 82% of children presenting to the hospital with ARTI [4, 5]. Among children
with single virus infections, the relative incidence of influenza virus (10%) was lower
compared to respiratory syncytial virus (43%) and human rhinovirus (33%) as described
by others [4, 5, 9]. Influenza-like illness, defined as an acute febrile respiratory tract
infection, was observed in ~90% of influenza cases and ~25% of other single virus infec-
tions. Our findings corroborate with previous studies that ILI is a poor predictor of
laboratory-confirmed infection and varies during the course of the influenza season [6– 9].
The accuracy of symptom-based influenza diagnosis was limited because other virus
infections shared similar symptoms. Moreover, presenting symptoms could not differ-
entiate between different virus infections due to common shared signs and symptoms,
a high frequency of mixed viral infections and relative incidence differences. Low
numbers and the relatively mild influenza presentations were probably due to a low
virus activity during 2006 and 2007 winter seasons and do not allow conclusions to be
generalized to other seasons. From the findings of our study, we conclude that PCR
diagnostics are required to firmly establish a virus-specific diagnosis in the clinical
setting and to guide antiviral treatment. Future molecular studies should re-evaluate the
relative incidence and clinical evaluation of different respiratory viruses in a prospective
study design using a more complete virus panel. Recent temporal clusters of acute flaccid
paralysis and cranial nerve dysfunction associated with a newly recognized respiratory
virus (enterovirus D68) serve as a clinical reminder that molecular diagnostics should
include new respiratory viruses to fully comprehend the clinical impact of respiratory
virus infections and to improve clinical management [10].  
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Severe influenza virus infections in children 
The combined clinical descriptions in chapters 2 and 3 support the general knowledge
that influenza infections among children in the hospital setting are often mild but that
life-threatening events do occur [11, 12]. In chapter 3, we describe two children with severe
influenza-associated encephalopathy (IAE), multiple organ failure and shock. Fortunately,
this clinical entity is extremely rare but it remains poorly defined and not universally
recognized. The children were infected with influenza A (H3N2) Fujian 2002 lineage virus
drift variants (Fujian/411/02-like and Wyoming/003/03-like) which were associated with
a high activity and frequent pediatric complications during the 2003-2005 seasons [13, 14].
The two children in this study had clinical manifestations that were similar to severe
IAE cases in Japan [15]. Previous studies report occasional detection of influenza RNA in
cerebrospinal fluids but neuro-invasion remains controversial [15– 18]. In an attempt to
confirm or refute virus dissemination and replication in different organs, we performed
pathological and molecular studies following parental permission  for autopsy and
developed a new M2 mRNA PCR as a molecular confirmation for viral replication. In this
study, pulmonary pathology findings were compatible with primary viral pneumonia [19]
and active viral replication was confirmed by immunohistochemistry and M2 mRNA PCR.
Similar pulmonary findings are reported to accompany other fatal cases of influenza-
associated encephalopathy in Japan [20, 21]. In our case, the brain and other organs
contained influenza RNA but lacked evidence of viral replication by immunohistochem-
istry and M2 mRNA PCR. The low-level presence of influenza RNA and absence M2 mRNA,
suggested a residual deposition of genomic RNA from replication elsewhere (lungs).
Influenza RNA in the brain may be the result of an increased permeability of the blood-
brain barrier as described by others [18]. Recent studies confirm that influenza RNA can be
detected in the blood of patients with severe illness [22, 23]. The lack of virus replication in
the brain implicates pro-inflammatory cytokines in the pathogenesis [24]. Unfortunately
cytokine diagnostics were not performed in serum or cerebrospinal fluid in our study.
Accumulating evidence in literature indicate that elevated cytokines in serum and CSF
(IL-6, IL-10, TNF-α, sTNF-R1 and IL-6) are correlated with onset and adverse outcomes of
IAE [25, 26]. An ongoing inflammatory reaction will not sufficiently be contained by
antiviral agents, therefore additional high-dose steroids and plasmapheresis may be
considered in similar cases [27]. Future studies should evaluate if virus RNA and high
levels of cytokines in serum and CSF can serve as markers to predict clinical severity
and outcome. Routine annual influenza vaccination is not offered to children in the
Netherlands but may be considered during clinical relevant drift seasons.
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Molecular detection of influenza outbreaks in
nursing homes 
Nursing homes continue to experience common influenza outbreaks that are associated
with a high morbidity among elderly residents despite nationwide vaccination pro -
grammes [28, 29]. Rapid diagnostic influenza outbreak confirmation is highly important to
implement timely infection control measures. Control measures include (re)vaccination of
elderly and health care workers, active surveillance, transmission precautions and early
antiviral treatment [30]. The study in chapter 4 evaluated different sampling techniques,
logistical support and laboratory diagnostic methods to optimize diagnostic confirmation
of influenza outbreaks in nursing homes. Nasopharyngeal swabbing was better tolerated,
more practical and equally sensitive compared to nasopharyngeal washings and more
sensitive than throat swabs (mean difference PCR cycle threshold value 4.7, P = 0.005). The
sensitivities of virus cultures (54%) and immunoassays (38% using nasopharyngeal swabs)
were low compared to PCR. Sampling methods and symptom duration likely determined
the sensitivity of immunoassays as described by others [31]. Immunoassays remain
attractive for their convenience, speed and positive predictive value, but negative results
always require PCR confirmation. A recent Norwe gian study confirmed our findings that
nasopharyngeal swabs are the sampling method of choice and provided new evidence that
nylon flocked swabs could improve the sensitivity compared to rayon swabs (mean
difference CT 2.3, P = <0.017) [32]. Outbreak team logistical support shortened diagnostic
intervals but this remains to be confirmed by others. We now recommend the use of
nasopharyngeal nylon flocked swabs, real-time PCR and logistical support for the rapid
confirmation of influenza outbreaks in nursing homes. Remarkably, the majority of elderly
influenza cases were vaccinated (82%) whereas the viruses always matched the corre-
sponding vaccine strains. These findings are in line with other studies which show that
influenza outbreaks continue to occur in nursing homes with high vaccine coverage rates
and vaccine match [33– 35]. A probable explanation for these ‘vaccine failures’ is that
standard-dose influenza vaccines have a low effectiveness in elderly people (~45–70%
protection) [29, 36]. Recent studies demonstrate that high-dose vaccines or mid-season
boosting result in higher antibody responses, more protective titres and a 25% reduction
of laboratory-confirmed infection [37, 38]. High-dose immunogenic vaccines may be
considered among frail elderly people in nursing homes and new studies should confirm
their immunological and clinical effectiveness. The exciting discovery of human broadly-
neutralizing or Fc-effector mediated human antibodies that target the hemagglutinin stalk
hold great promise for the future development of more universal influenza vaccines [39, 40].
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Prolonged influenza virus infection in the
immunocompromised host
Influenza antiviral treatment is associated with a lower risk of pneumonia and mortality
among high-risk patients in the clinical setting [41, 42]. Until 2007, oseltamivir-resistant
viruses were rare and deemed incapable of circulating due to compromised viral fitness
and transmissibility [43– 45]. The emergence of oseltamivir-resistant seasonal A (H1N1)
viruses during the 2007-2008 season was of great concern and the origin remained
unclear [46– 48]. In chapter 5, we describe the results of a study to identify clinical sources
of drug-resistant influenza viruses. Earlier studies reported anecdotal immunocompro-
mised patients who developed drug-resistant viruses during therapy but these incidences
were considered extremely rare [49– 52]. During a 3-year period, we demonstrated that 8
adult hematology-oncology patients with lymphopenia manifested prolonged influenza
virus excretion and frequent development of drug-resistant viruses (67% of eligible
patients) in a single medical center. Complete viral clearance correlated with lymphocyte
reconstitution. We hypothesized that immunocompromised patients with prolonged
viral excretion due to (functional) lymphopenia often develop resistant virus. Later
animal and human clinical studies now support this hypothesis [53]. Recent studies show
that immunocompromised patients are more at risk to develop resistant viruses
compared to immunocompetent patients [54, 55]. Large studies confirm that hematology-
oncology patients often manifest high levels of prolonged virus excretion [56] and develop
resistant viruses in 45–58% of cases [52, 57]. We are concerned that antiviral resistance and
viral LRTI are more common in hematology-oncology patients [58]. Independent risk
factors for influenza LRTI include age, lack of (early) antiviral treatment, profound
lymphopenia and HSCT donor mismatch [41, 59– 61]. Future studies should further evaluate
host risk factors predisposing for the development of drug-resistant viruses and viral
LRTI. Our study findings confirm that antiviral resistance monitoring  is important. New
real-time PCR assays are now available to improve early diagnostics to guide antiviral
treatment and clinical management [62]. Oseltamivir treatment seems to prevent viral
LRTI [41, 42] but antiviral protection is hampered by drug-resistant viruses [53, 63, 64].
Alternative treatment regimens using available drugs (high-dose oseltamivir, combined
oseltamivir with inhaled zanamivir, and triple-combination antiviral drug) may raise the
genetic barrier but appear to lack superiority to standard-dose oseltamivir [65– 69]. We
recommend that future studies should concern the development of new antiviral agents
and alternative routes of drug administration (e.g. intravenous zanamivir). In addition,
the clinical role of host immune responses remains to be elucidated.
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Hospital transmission of oseltamivir-resistant
influenza virus 
Before 2008, it was assumed that oseltamivir-resistant influenza viruses could not
circulate and cause relevant illness due to compromised transmissibility and atten-
uated pathogenicity. In chapter 6, we provide new evidence that H275Y oseltamivir-
resistant A (H1N1) viruses readily transmitted between patients in a hospital setting.
Later epidemiological studies confirmed a global spread of H275Y influenza
A/Brisbane/59/2007-like antigenic drift variants which replaced the wild-type
A/Solomon Islands/3/2006 virus [70– 73]. Previous assumptions that NAI-resistance
invariably compromised virus fitness were no longer valid [74]. A scientific explanation
for this unabated spread of H275Y virus remained elusive until genetic studies demon-
strated that permissive NA gene mutations (R222Q, V234M, D344N and D354G) restored
deficient virus fitness by improving NA folding, surface expression and sialic acid
affinity [75– 77]. In our study, H275Y virus retained significant pathogenicity in high-risk
patients with lymphopenia who manifested viral LRTI (3 patients) and associated
mortality (2 patients). Lymphopenia is a known risk factor for viral LRTI and mortality
[41, 59– 61]. Patient 4 manifested a remarkable relapse of viral LRTI and ARDS during
sustained profound lymphopenia. Physicians should remain vigilant and may consider
re-administration of antivirals to patients with sustained profound lymphopenia to
prevent relapses of severe viral LRTI and ARDS [78, 79]. We underscore that antiviral
susceptibility monitoring is important to guide influenza treatment and control [46, 70].
Unfortunately, oseltamivir treatment is hampered by drug-resistant viruses due to
treatment failures [53, 63, 64]. Inhaled zanamivir is effective for mild [63] but not for
severe influenza LRTI due to the risks of broncho spasms and clogging of ventilator
tubes [80– 82]. The lack of alternative antiviral treatment options is of great concern and
we recommend new clinical evaluations of investigational intravenous zanamivir and
development of new antiviral agents and multidrug regimens. Our study describes
the new clinical implementation of computational phylogenetic analysis using
 appropriate virus controls for the unequivocal molecular confirmation of oseltamivir-
resistant influenza A (H1N1) virus outbreaks in the clinical setting.  Later studies have
used similar computational  phylogenetic assays to confirm the emergence and spread
of new oseltamivir-resistant influenza A(H1N1)pdm09 viruses in hematology-oncology
wards in the USA and in the UK (Figure 1) [83, 84].  Future antiviral resistance surveillance
studies should monitor permissive and antiviral resistance mutations in the clinical and
community setting.
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Figure 1.   Maximum-likelihood tree of concatenated HA and NA genes of A(H1N1)pdm09
hospital outbreak strains, unlinked clinical strains and community surveillance strains
in Wales and the United Kingdom.           
The tree was rooted on A/California/07/2009 and bootstrap values are displayed in brackets. Oseltamivir-resistant viruses are in bold
marked with #. OT = oseltamivir treatment.  
Source: adapted from [84].
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Molecular surveillance of influenza A(H1N1)pdm09 virus
In chapter 7, we evaluated the accuracy of mass spectrometry-based comparative
sequence analysis (MSCSA) to monitor virulence and oseltamivir-resistance markers in
70 surveillance specimens and 35 selected clinical specimens obtained during the 2009
H1N1 pandemic. MSCSA and Sanger sequencing results revealed a high concordance
(nucleotides >99%, SNPs ~94%) and MSCSA may therefore be used to screen for
influenza virulence markers. All surveillance specimens had wild-type virulence marker
sequences in PB2,  PB1-F2  and NS1 genes and stop codons in PB1-F2  and NS1 genes.
Remarkably, PB2 gene lacked 627K or 701N mammalian signature changes that facil-
itate replication at low temperatures [85, 86]. Recent studies unveil that PB2 gene G590S
and Q591R compensate for reduced polymerase activities [87]. Reverse genetics studies
show that PB2-627K and PB2-701N do not increase replication and pathogenicity [88, 89].
Restored NS1 and PB1-F2 expression or PB1-F2-N66S mutation do not appear to alter
virulence in the current genetic background [90, 91]. New mutations (PB2-T271A, PB2-
H357N, PA-A36T, PB2-E158G and PB2-T558I) may increase polymerase activity, replication
kinetics and pathogenicity and should be monitored [92– 95]. We conclude that genetic
surveillance should include new polymorphisms and should not rely on known
virulence and resistance markers [87]. In our study, real-time PCR detected H275Y
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Figure 2.   Emergence of V241I and N369K permissive mutations in circulating A(H1N1)pdm09 viruses.
Source: adated from [108].
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oseltamivir-resistant A(H1N1)pdm09 virus in 19/35 clinical specimens. MSCSA only
detected H275Y in fully mutant virus populations (4/4) but not in mixed populations
(0/15) and is not suitable to screen for resistance markers in the clinical setting. Other
studies report similar anecdotal H275Y A(H1N1)pdm09 viruses [96– 103] with a compro-
mised fitness [75]. In 2010-2011, small H275Y community clusters appeared in the UK and
USA among cases with no prior oseltamivir treatment exposure [104, 105]. Later epidemi-
ological studies uncovered large widespread H275Y clusters in Australia [106] and
Japan [107] caused by viruses with new permissive NA gene mutations (V241I, N369K)
that emerged in 2010 (Figure 2) [108]. New permissive mutations are now present in >99%
of circulating A(H1N1)pdm09 viruses and enhance NA gene expression/activity and
restore H275Y virus replication/transmission fitness [108, 109]. Fortunately, wild-type
viruses still appear to outcompete H275Y viruses (Figure 3) [107]. Epidemiological
antiviral resistance monitoring is important and may uncover new relevant polymor-
phisms and unexpected large clusters [100, 107, 110]. Future studies may evaluate the use
of improved next generation (deep) sequencing methods for whole-genome influenza
sequencing using standardized data analysis pipelines [111– 114]. 
Figure 3.   Circulating H275Y virus was replaced by wild-type A(H1N1)pdm09 virus in Hokkaido, Japan.
Source: adated from [107].
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Host immune responses dictate influenza outcome in
hematology-oncology patients
In chapter 8, we evaluated the role of humoral and cell-mediated immune responses in
determining A(H1N1)pdm09 virus symptoms and viral clearance in six hematology-
oncology patients with prolonged viral excretion. The clinical role of host immune
responses remains unclear since immune monitoring studies are lacking in humans.
The results in chapters 5 and 8 suggest that prolonged viral excretion and viral
clearance are correlated with T-cell lymphopenia and influenza virus-specific T-cell
responses respectively. Humoral responses were not correlated with viral clearance
since three patients manifested ongoing viral excretion during seroprotective HI
titers [115, 116]. Our findings corroborate with virus challenge studies in healthy volun-
teers that correlated virus-specific T-cells with influenza host immunity [117] and with
human CMV studies that correlated virus-specific T-cells with viral clearance [118]. CD4+
and CD8+ influenza virus-specific T-cell responses circulate for only ~30 days after
infection and are associated with recent active infection (Figure 4) [119]. We evaluated
host protective immune responses during prolonged influenza virus excretion. Clinical
protection with sustained mild symptoms was associated with the presence of CD8+
T cells in two patients and with additional CD16+ FcIgG cell-mediated immunity in one
case. Four patients developed severe viral LRTI during profound T-cell lymphopenia and
(transient) absence of ADCC. More knowledge on protective immune responses is
awaited to improve the clinical management of high-risk patients. New antiviral
strategies may include favipiravir or NAI combination treatments but the clinical
relevance is unclear [120, 121]. We further evaluated possible adverse innate and adaptive
cell-mediated immune responses to elucidate correlates of viral ARDS immuno -
pathogenesis during prolonged viral excretion. Previous studies suggested that T-cell
responses are important determinants of influenza immunopathology [122]. In this
study, viral ARDS manifested during remarkable profound T-cell lymphopenia and
coincided with innate cell reconstitution. These findings concur with recent animal
models which show that innate cell recruitment elicit a viral cytokine storm and
immunopathology [123, 124]. Recent studies show that severe human influenza infections
manifest hypercytokinemia [24– 26, 125, 126]. New treatments using sphingosine analogs
effectively temper immune pathology in animal models and may be promising
in humans [127, 128]. We conclude that a wide range of host immune responses determine
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influenza outcome and viral clearance. This study is limited by a low number of patients
and we therefore recommend large immune monitoring studies to confirm the clinical
role of different immune responses and to evaluate new treatment options. 
Figure 4.   The percentages of virus-specific CD8+ (a) and CD4+ (b) influenza (H1N1)pdm09
virus-specific T-cells in individual patients at different time points after infection onset.
Source: adated from [119].
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Conclusion 
The studies described in this thesis demonstrate that influenza molecular diagnostic
assays are indispensable in the clinical setting. Reverse-transcriptase PCR methods
allow for the sensitive and accurate identification of single and mixed respiratory virus
infections including human influenza viruses. New molecular diagnostic assays are
helpful to explore and redefine relevant virus characteristics, clinical manifestations
and epidemiology. Prospective studies are awaited to characterize and establish the
relative incidence of respiratory virus infections including influenza virus infections in
different patient groups and clinical settings. We demonstrate that improved diagnostic
sampling, specimen logistics, and laboratory diagnostics can optimize the clinical
management of individual patients and the rapid implementation of control measures.
Our studies provide evidence that new molecular diagnostic assays can detect virus
expression, resistance mutations and virulence markers, and that computational phylo-
genetics provide accurate and practical confirmation of virus outbreaks in the clinical
setting. In this thesis we show that influenza-infected hematology-oncology patients are
at risk to develop antiviral-resistant virus during prolonged viral excretion and that
resistant viruses are transmissible and retain pathogenicity. We performed human
immune monitoring studies which suggest that T cells are important for clinical
protection and viral clearance. Our study findings indicate that ADCC may provide
important clinical protection and that influenza immunopathology is mediated by
innate immune cells. Future studies should evaluate the clinical effectiveness and
efficacy of high-dose influenza vaccines and new antiviral agents including favipiravir.
The research and clinical development of hemagglutin stem-only ‘universal’ influenza
vaccines [129, 130], anti-HA stalk monoclonal-antibody treatments [131] and novel immu -
no modulating therapeutic approaches (e.g. sphingosine analogs) is highly anticipated
[127, 128]. The results from this thesis demonstrate that molecular tools revolutionize
influenza laboratory diagnostics and improve our clinical understanding of this contin-
uously evolving virus. The inherent viral genetic variability and antigenic plasticity is
a continuous incentive for new research to keep up with relevant mutations and to
outsmart the virus.
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Samenvatting (Summary in Dutch)
Influenza of griep is bij de mens een veelvoorkomende infectieziekte van de luchtwegen
die meestal wordt veroorzaakt door influenzavirussen type A en B. Humane influenza A
virussen worden onderverdeeld in subtypen op basis van de oppervlakte-eiwitten
hemagglutine (H1, H2, H3) en neuraminidase (N1, N2). Daarnaast circuleren twee
influenza B virus genetische lijnen. Influenza A(H1N1), A(H3N2), B(Yamagata) en
B(Victoria) virussen veroorzaken jaarlijks een seizoensgebonden epidemie in de herfst-
en winterperioden en ontwijken de immuniteit van de mens door mutaties en verande-
ringen in de oppervlakte-eiwitten, ook antigene drift genoemd. Een pandemie ontstaat
wanneer een dierlijk influenzavirus overspringt naar de mens (meestal vanuit varkens)
en zich efficiënt verspreidt in een bevolking zonder of met een beperkte immuniteit,
zoals bij de pandemieën van 1918 A(H1N1), 1957 A(H2N2), 1968 A(H3N2) en 2009 A(H1N1).
In 2009 ontstond een relatief milde pandemie die werd veroorzaakt door een nieuw
influenza A(H1N1)pdm09 virus dat genetisch bestond uit elementen afkomstig uit
Noord-Amerikaanse varkens influenza, Euro-Aziatische varkens influenza, Noord-
Amerikaanse aviaire influenza en een menselijk griepvirus. Dergelijke grote verande-
ringen van influenza A virus worden aangeduid als antigene shift. Het influenza
A(H1N1)pdm09 virus bevatte genetische elementen waarin bekende virulentie en
antivirale resistentie kenmerken echter ontbraken.
Seizoensgebonden influenza verloopt meestal ongecompliceerd. Acute symptomen
beginnen met koorts en keelpijn, gevolgd door spierpijn, hoofdpijn en andere luchtweg-
klachten. De patiënt voelt zich beroerd maar de klachten gaan bijna altijd binnen 7 dagen
vanzelf over. Ouderen (leeftijd ≥65 jaar) en mensen met een chronische ziekte (hart- en
vaatziekten, longaandoeningen, ernstige nierinsufficiëntie, verminderde weerstand en
diabetes mellitus) behoren tot risicogroepen met een verhoogd risico op pneumonie
complicaties, ziekenhuisopnames en sterfte door de gevolgen van griep. Risicogroepen
krijgen daarom jaarlijks een gratis griepvaccinatie aangeboden in het kader van het
Nationaal Programma Grieppreventie. Influenzainfecties verlopen bij tevoren gezonde
kinderen en jongvolwassen mensen meestal ongecompliceerd en zelflimiterend,
waardoor vaccinatie en antivirale behandeling bij deze groep niet noodzakelijk is.
Antivirale neuraminidaseremmers kunnen de ziekteduur en complicaties verminderen
indien de behandeling binnen 48 uur na aanvang van de klachten is gestart. In het geval
van ernstige influenzainfectie bij patienten in het ziekenhuis verlaagt het middel het
risico op mortaliteit indien binnen 96 uur is gestart. Het stellen van de diagnose op basis
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van symptomen blijkt weinig betrouwbaar en de conventionele diagnostiekmethoden als
serologie en viruskweek zijn traag en weinig gevoelig. Hierdoor is er een toenemende
behoefte aan de ontwikkeling en het gebruik van moleculaire diagnostiek in de klinische
praktijk. Dit proefschrift beschrijft een breed scala aan onderwerpen die gerelateerd zijn
aan de toepassing van influenza moleculaire diagnostiek en de interpretatie van de
gevolgen van seizoensgebonden en pandemische influenza, bij patiënten met een verschil-
lende klinische achtergrond. 
De achtergrond van influenzavirussen en aanleiding tot dit proefschrift
In hoofdstuk 1 wordt een introductie gegeven van de geschiedenis en achtergrond
humane van influenzavirussen, de epidemiologie van seizoensgebonden en pandemische
influenza en het klinisch spectrum bij gezonde mensen en risicogroepen. De ont -
wikkelingen op het gebied van influenzavirusdiagnostiek, antivirale behandeling en
vaccinatie worden beschreven evenals de beperkte kennis over antivirale resistentie-
vorming en virale pathogenese bij immuungecompromiteerde patiënten. Tenslotte staan
de doelstellingen en indeling van dit proefschrift beschreven. Deze doelstellingen zijn: (1)
het evalueren van real-time PCR diagnostiek methoden en beschrijven van klinische
aspecten van influenza, (2) het onderzoeken van de precisie en toepasbaarheid van
massaspectrometrie en  mole culaire technieken voor de detectie van resistentie en
virulentie mutaties en (3) het correleren van het gastheerimmuunsysteem met virus-
 eliminatie, symptomen, en anti virale resistentie vorming.
Moleculaire detectie van acute respiratoire virusinfecties bij kinderen 
Het klinische spectrum van influenza en andere respiratoire virussen is wetenschappelijk
onderbelicht bij jonge kinderen met acute luchtweg klachten in het ziekenhuis. Hoofd -
stuk 2 beschrijft een studie waarbij 274 kinderen met acute luchtwegklachten in het
ziekenhuis gedurende twee winterseizoenen in 2006 en 2007 op respiratoire virussen
werden onderzocht met het gebruik van multiplex real-time PCR. De meeste kinderen
(n=236) waren jonger dan 3 jaar en een virusinfectie kon bij 82% van alle kinderen worden
bewezen. Individuele virusinfecties  (59%) werden vaker aangetoond dan gemengde virus-
infecties (23%). Het respiratoir syncytieel virus en humaan rhino virus werden nadruk -
kelijk het meest aangetoond en waren significant vaker aantoonbaar bij jonge kinderen
dan influenza (p<0.0001). In een subanalyse werden virus-geassocieerde symptomen en
klinische uitkomsten onderling vergeleken bij kinderen jonger dan 3 jaar. Individuele
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virusinfecties konden niet gekoppeld worden met specifieke symptomen omdat verschil-
lende virussen dezelfde symptomen deelden en gemengde virusinfecties frequent voor -
kwamen. Virus-geassocieerde klinische uitkomsten toonden dat het respiratoir syncytieel
virus en humaan rhinovirus respectievelijk vaker in verband konden worden gebracht met
zuurstoftoediening en ernstige complicaties. De conclusies waren dat respiratoire virussen
frequent worden gevonden bij kinderen met acute luchtwegklachten in het ziekenhuis.
PCR diagnostiek is nodig voor het stellen van de diagnose omdat klinische symptomen niet
onderscheidend zijn. Respiratoir syncytieel virus en humaan rhinovirusinfecties geven de
hoogste ziektelast bij jonge kinderen. De resultaten suggereren dat influenzavirusinfecties
bij kinderen in het ziekenhuis relatief mild verlopen, maar algemene conclusies kunnen
niet geformuleerd worden door de lage aantallen. Het is bekend dat levensbedreigende
influenzavirusinfecties kunnen voorkomen bij kinderen. 
Kinderen met ernstige influenzaviruspneumonie 
De pathogenese van ernstige influenzavirusinfecties bij kinderen is grotendeels
onbekend. In hoofdstuk 3 worden de klinische beelden en pathologische bevindingen
beschreven van twee kinderen die zijn overleden aan een ziektebeeld met influenza -
viruspneumonie, diffuse intravasale stolling, encephalopathie en multi-orgaanfalen. Na
specifieke toestemming van ouders zijn histopathologische en moleculaire studies uitge-
voerd om de aanwezigheid van influenzavirus in longen en andere organen en gerela-
teerde weefselschade te bestuderen. Immuunhistochemische kleuringen en innovatieve
moleculaire bepalingen zijn uitgevoerd om de aanwezigheid van replicerend virus te
onderzoeken in de luchtwegen en andere orgaan weefsels. Pathologie resultaten toonden
een bronchitis en vroege diffuse alveolaire schade in de longen met histopathologisch en
moleculair bewijs voor virus replicatie in de bronchiën en enkele alveolaire cellen.
Influenzavirus RNA werd sporadisch aangetoond in organen buiten de longen zonder
histopathologische of moleculaire aanwijzingen voor virusreplicatie. Wij concludeerden
dat ernstige influenza bij kinderen zich kan manifesteren met diffuse intravasale stolling,
encephalopathie en multi-orgaanfalen en dat bij soortgelijke klinische presentaties
influenza dient te worden uitgesloten. De afwezigheid van virus replicatie buiten de
longen onderbouwt de hypothese dat fulminante symptomen worden veroorzaakt door
een systemische afgifte van proinflammatoire cytokinen. Het aanbieden van influenza-
vaccins aan kinderen moet worden overwogen tijdens seizoenen, wanneer zeldzame
virulente influenza A drift varianten ontstaan door intra-subtypische genetische reassor-
tering, zoals waargenomen in 2003 en 2004 met influenza A/H3N2/Fujian/411/02 virus.  
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Moleculaire detectie van influenzavirusinfecties in verpleegtehuizen 
De studie in hoofdstuk 4 vergelijkt de gevoeligheid van influenzavirus real-time PCR,
virus kweek en antigeen sneltesten op diverse respiratoire materialen verkregen uit 6
verpleegtehuizen met influenza verspreiding in 2005 en 2006. De meerwaarde van logis-
tieke ondersteuning door Gemeentelijke gezondheidsdienst (GGD) ‘outbreak teams’ werd
tevens geëvalueerd. Met behulp van PCR werd influenzavirus in 80% van de 85 verkregen
materialen en bij 81% van de 47 onderzochte bewoners aangetoond. De gevoeligheid van
viruskweek (54%) en antigeen sneltest (22%) waren laag vergeleken met PCR en hiermee
werd influenza verspreiding in enkele verpleegtehuizen gemist. De semi-quantitatieve
PCR gevoeligheid van nasopharynx spoelsels en nasopharynx uitstrijken waren verge-
lijkbaar maar wel 10–100 keer gevoeliger dan bij keel uitstrijken. Influenza-geïnfecteerde
ouderen waren meestal gevaccineerd (82%) en gekweekte virussen kwamen overeen met
het vaccin. Nasopharynx spoelsels waren niet goed uitvoerbaar bij ouderen. Met GGD
logistieke ondersteuning werd een uitslag eerder gegenereerd (gemiddeld na 28.2 uur)
dan zonder ondersteuning (gemiddeld na 84 uur) (P = 0.05). Wij concludeerden dat PCR
diagnostiek uitgevoerd op nasopharynx uitstrijken met GGD logistieke ondersteuning het
meest praktisch, gevoelig en snel is. De studie resultaten dragen bij aan een structurele
verbetering van influenzadiagnostiek in verpleeghuizen. De resultaten tonen aan dat
conventionele influenzavaccins een lage bescherming bieden aan ouderen en dat hogere
dosis influenzavaccins dienen te worden overwogen. 
Langdurige influenzavirusinfecties bij immuungecompromiteerden  
Hoofdstuk 5 beschrijft een studie waarin ziekenhuis patiënten met ≥14 dagen
langdurige influenzavirusinfectie klinisch en virologisch werden geëvalueerd tussen
2005 en 2008. Er werden 8 immuungecompromiteerde patiënten geïdentificeerd met
een hematologisch (n=1) of hemato-oncologisch (n=7) ziektebeeld. Langdurig virus
excretie kon worden geassocieerd met lymfocytopenie (8/8 patiënten) en niet met granu-
locytopenie (2/8 patiënten) of monocytopenie (2/8 patiënten). Zes patiënten ontwik -
kelden een zuurstof-afhankelijke influenza-geassocieerde lage luchtweginfectie en
antivirale therapie met neuraminidase-remmers (meestal oseltamivir) was gecorreleerd
met klinische verbetering (P = .02). Virus-eliminatie was geassocieerd met lymfocyten
reconstitutie (P = .04) maar niet met oseltamivir behandeling. Twee van de 3 patiënten
die aanvullend onderzocht werden ontwikkelden een resistent virus tijdens antivirale
therapie. Wij concludeerden dat lymfocytopenie geassocieerd is met een langer bestaande
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influenzavirusinfectie, het ontwikkelen van influenza-geassocieerde lage luchtwegin-
fecties en met het ontstaan van antivirale resistente virussen. Antivirale behandeling is
geassocieerd met klinische verbetering maar niet met virus-eliminatie. Virus-eliminatie
lijkt afhankelijk van de gastheerimmuniteit waarin lymfocyten een sleutelrol spelen. Deze
nieuwe klinische inzichten zijn belangrijk voor het herkennen van risicofactoren voor het
ontwikkelen van respiratoire complicaties en antivirale resistentie. 
Oseltamivir-resistent influenzavirus in het ziekenhuis
In hoofdstuk 6 wordt de verspreiding van een oseltamivir-resistent seizoens gebonden
influenza A(H1N1) virus beschreven. In februari 2008 werd een epidemiologisch cluster
van patiënten met ernstige influenzavirus symptomen waargenomen binnen het
ziekenhuis. Sequentieanalyse van de hemagglutinine en neuraminidase genen van
influenza A(H1N1) virussen van de 4 patiënten werden vergeleken met de sequentie -
gegevens van ongerelateerde virussen binnen het ziekenhuis, de Leidse regio en in de
Nederlandse samenleving. De moleculaire gegevens toonden een fylogenetisch cluster
van oseltamivir-resistente virussen met een H274Y mutatie (volgens N2 nummering) in
het neuraminidase gen wat bewijzend was voor de verspreiding van het virus binnen het
ziekenhuis. Drie patiënten met lymfocytopenie ontwikkelden tijdens infectie een influ-
enzapneumonie, waaraan 2 overleden. Histopathologische, moleculaire en micro -
biologische bevindingen waren consistent met een influenzaviruspneumonie bij een van
de patiënten. Wij concludeerden dat seizoensgebonden oseltamivir-resistent influenza
A(H1N1) virus met een H274Y neuraminidasegenmutatie evident overdraagbaar is en
ernstig ziekmakend kan zijn bij hoog-risico patiënten. De nieuwe klinische inzichten van
deze studie zijn dat unieke influenzavirus clusters moleculair kunnen worden aange-
toond in het ziekenhuis en dat oseltamivir-resistente influenzavirussen niet altijd
intrinsiek verzwakt en niet-overdraagbaar zijn, zoals eerder werd aangenomen. 
Moleculaire surveillance van influenza A(H1N1)pdm09 virus
In hoofdstuk 7 onderzochten wij de toepasbaarheid en precisie van ‘massaspectro-
metrie gebaseerde vergelijkende sequentie analyse’ (mass spectrometry-based compa-
rative sequence analysis, MSCSA) tijdens de influenzapandemie van 2009. De genetische
virulentie en resistentie kenmerken van het influenza A(H1N1)pdm09 virus werden met
MSCSA geëvalueerd bij patiënten die in een vroeg stadium van de influenzapandemie
besmet waren. Bij MSCSA, wordt het virus RNA na enzymatische ampli ficatie omgezet
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naar DNA, waarna het DNA met restrictie-enzymen wordt geknipt. Met behulp van een
massaspectrometrie worden de lading en massa van de kleine DNA stukjes semiauto-
matisch afgelezen. Softwarematig worden lading en massa omgerekend en vergeleken
met virus database sequenties om mutaties op te sporen. Bij dit onderzoek werden
surveillancematerialen van 70 patiënten verkregen tijdens de eerste pandemische golf
uit Leiden en omgeving in de zomer van 2009. De materialen werden onderzocht op
bekende virulentiemutaties in PB1-F2, PB2 en NS1 genen en resistentie mutaties in het
neuraminidase (NA) gen. Sanger sequencing en MSCSA  resultaten werden met elkaar
vergeleken en waren vergelijkbaar. Er werden geen nieuwe virulentie of resistentie
kenmerken gevonden. Aanvullend werden 35 materialen verkregen van 4 immuunge-
compromiteerde patiënten met ≥14 dagen langdurige virus excretie onderzocht op NA
gen H275Y oseltamivir resistentie mutaties (volgens N1 nummering) met behulp van
H275Y real-time PCR, Sanger sequencing en MSCSA. H275Y mutatie werd met behulp
van real-time PCR gedetecteerd in 19 van de 35 materialen, terwijl de gevoeligheid van
Sanger sequencing 89% (17/19) en MSCSA 24% (4/19) beduidend lager was. MSCSA
software kon de aanwezigheid van H275Y mutaties niet goed interpreteren in patiënt-
materialen met gemengde viruspopulaties. Wij concludeerden dat MSCSA gebruikt kan
worden voor de moleculaire surveillance van influenza A(H1N1)pdm09 virus maar dat
de gevoeligheid te laag is voor het detecteren van H275Y mutaties in patiëntenmateriaal. 
Gastheerimmuniteit bij langdurige influenzavirusinfectie 
In hoofdstuk 8 onderzochten wij de klinische betekenis van humorale en cellulaire
gastheerimmuniteit bij het ontwikkelen van virus-geassocieerde symptomen en virus-
eliminatie bij hematologie-oncologie patiënten met langdurige influenzavirusinfectie.
In totaal werden 6 volwassen hematologie-oncologie patiënten met ≥14 dagen influenza
A(H1N1)pdm09 virusinfectie prospectief geïncludeerd tussen november 2009 en april
2013. Realtime-PCR diagnostiek werd verricht naar influenza A(H1N1)pdm09 virus en
neuraminidase gen H275Y oseltamivir resistentie mutatie. Leukocyten differentiatie,
lymfocyten subsets, virus-specifieke hemagglutine-inhibitie (HI) antistof titers en virus-
specifieke T-cellen werden vergeleken met virus-geassocieerde symptomen en virus-
eliminatie. Beschermende HI titers (HI ≥80) tegen homoloog virus werden samen met
aanwezige CD16+ effector cellen gecombineerd beschouwd als een surrogaatbepaling
voor de aanwezigheid van antistof-afhankelijke cellulaire cytotoxiciteit (antibody-
dependent cell-mediated cytotoxicity, ADCC). Wij concludeerden dat langdurige influ-
enzavirusinfectie specifiek geassocieerd was met T-cel lymfocytopenie. CD8+ T-cel en
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ADCC activiteit bieden klinische bescherming tijdens langdurige virale excretie.
Definitieve virus-eliminatie kwam tot stand door gecombineerde virus-specifieke CD4+
en CD8+ T-cel activiteit en kon niet worden geassocieerd met antivirale therapie, HI
seroconversie of ADCC activiteit. Longinsufficiëntie door ‘acute respiratory distress
syndrome’ werd klinisch waarschijnlijk veroorzaakt door excessieve inflammatoire
reacties aangezet door de aangeboren niet-specifieke cellulaire immuniteit, nadat het
virus in de afwezigheid van T-cel- en ADCC-gemedieerde bescherming de lagere com -
partimenten van de luchtwegen heeft bereikt.
Conclusie
De studies in dit proefschrift tonen aan dat moleculaire diagnostiek van grote waarde
is voor het aantonen van influenzavirusinfecties en antivirale resistentie in zorginstel-
lingen. Enkele nieuwe inzichten betreffende influenzavirusdiagnostiek en klinische
kenmerken beschreven in dit proefschrift zijn: (1) moleculaire diagnostiek van influen-
zavirus is superieur aan conventionele diagnostiek, (2) virus replicatie kan moleculair
in weefsels worden aangetoond, (3) virus verspreiding kan moleculair worden bewezen,
(4) oseltamivir-resistente virussen kunnen overdraagbaar en ziekmakend zijn, (5) CD4+
en CD8+ T-cel lymfocyten zijn bepalend voor virus-eliminatie, (6) CD8+ T-cel en ADCC
activiteit bieden klinische bescherming tijdens langdurige virale infectie en (7) virus-
geassocieerde longinsufficiëntie wordt waarschijnlijk voor een belangrijk deel aangezet
door de aangeboren niet-specifieke cellulaire immuniteit van de gastheer. Moleculaire
technieken zijn nu onmisbaar voor het snel en accuraat detecteren en karakteriseren
van influenzavirusinfecties in de klinische praktijk. Het is aanbevolen dat moleculaire
technieken in de toekomst toenemend gebruikt worden om de klinisch relevante
kenmerken van dit veranderlijk virus goed te kunnen vaststellen.
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